$MGCD Agrees To Be Acquired By Altus Capital Partners

SAINT PAUL, Minn., Nov. 27, 2017  — MGC Diagnostics Corporation, (Nasdaq: MGCD) a global medical technology company (“MGCD”), announced it has agreed to be acquired by affiliates of Altus Capital Partners, Inc. (“Altus”).  Altus is a private equity firm that makes control investments in middle market manufacturing businesses.

Altus will acquire all outstanding shares of MGCD for $11.03 per share in cash, or approximately $50.3 million.  Under the terms of the merger agreement, Altus will commence a tender offer for all MGCD outstanding shares as promptly as possible after November 27, 2017.  Upon completion of the transaction, which is expected to close in late 2017 or early 2018, MGCD will become a privately held company.

MGCD’s Board unanimously approved the acquisition agreement, which follows a review of strategic alternatives that the Company announced on January 25, 2017.  In addition, MGCD directors and officers representing 8.9% of the outstanding shares have entered into tender support agreements with Altus.

The purchase price represents a 44% premium to the January 24, 2017 closing price of $7.65, and premiums of 25% and 37% to the MGCD respective closing prices on the dates one day and three months prior to the date of the announcement.

The proposed transaction is subject to customary closing conditions and approvals and the tender of a majority of MGCD outstanding shares. The purchase price will be funded through equity commitments managed by Altus and senior and mezzanine commitments from third parties.

“After a review of strategic alternatives by our Board of Directors, we are pleased to reach this agreement with Altus, which provides our shareholders with immediate liquidity and substantial certainty of value,” said MGCD Board Chairman Mark Sheffert.  “We believe this transaction presents a winning proposition for all our stakeholders.  Altus is a strategic-minded and growth-oriented investor in the manufacturing space with a proven track record of partnering with company management.”

“We look forward to becoming part of the Altus organization,” said MGCD CEO Todd Austin.  Our strategies for product innovation and growth are nicely aligned and together we believe we can accelerate the delivery of new product offerings to our customers.  Altus’s financial strength provides incremental funding for our product development pipeline initiatives.”

Advisors

Craig-Hallum Capital Group LLC is acting as financial advisor to MGCD.

About MGC Diagnostics

MGC Diagnostics Corporation is a global medical technology company dedicated to cardiorespiratory health solutions. The Company, through its Medical Graphics Corporation and Medisoft SA subsidiaries, develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company’s products are sold internationally through distributors and, in the United States, France and Belgium, primarily through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians’ offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the anticipated closing date of the acquisition. These statements are based on current expectations, some of which may be beyond MGCD’s control. Among other things, these factors include the risk that the acquisition will not be completed or is delayed because the tender offer did not proceed as anticipated, or that the financing becomes unavailable, or closing conditions to the acquisition were not satisfied. For a further list and description of risks and uncertainties associated with MGCD, see its reports filed with the Securities and Exchange Commission, including the “Risk Factors” section in its most recent annual report on Form 10-K.

Additional Information

This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of MGCD.  Altus will be filing a Tender Offer Statement with the Securities and Exchange Commission and MGCD will be filing a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer.  MGCD shareholders are advised to read the Tender Offer Statement regarding the acquisition of MGCD referenced in this news release, and the related Solicitation/Recommendation Statement, when those statements are made available to them. The Tender Offer Statement and the Solicitation/Recommendations Statement will contain important information that each investor should read carefully before making any decision with respect to the offer. These documents will be made available to all shareholders of MGCD at no expense to them. These documents will also be available at no charge on the SEC’s web site at www.sec.gov. Shareholders may also obtain copies of these documents without charge by requesting them from MGCD at 350 Oak Grove Parkway, Saint Paul, Minnesota, 55127-8599.

$DPW to Present at 10th Annual @theLDMicro ‏Investor Conference

Company to Attend 4-Day Main Event; to Address Attendees on December 7th

FREMONT, Calif., Nov. 27, 2017 — Digital Power Corporation (NYSE.American:DPW) (“Digital Power” or the “Company“), a company seeking to increase revenues through acquisitions and organic growth, announced today that it will present at the 10th Annual LD Micro Main Event investor conference on Thursday, December 7th at 10:30 AM PST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Members of the Company’s executive management team will be presenting on behalf of the company and senior management will be available for one-on-one meetings during the event. The Company looks forward to establishing new relationships and meeting current investors and associates attending the event. The Company stated it will issue an investor update before the opening of the market on the morning of December 7, 2017. Topics will include an update on revenue guidance for the quarter and 2018, a progress report on the cryptocurrency initiative by Coolisys Technologies, advances made on the MTIX $50M purchase order and the advanced technology platform and an update on Digital Power Lending.

The LD Micro Main Event is the largest independent conference for small/micro-cap companies featuring 250 companies presenting to an audience of over 1,000 attendees. The LD Micro Conference is a 4-day event that features invitation-only presentations from both the most successful companies and the latest innovative firms.

View DPW’s LD Micro profile here: https://www.ldmicro.com/profile/DPW

ABOUT DIGITAL POWER

Headquartered in Fremont, CA, Digital Power Corporation, through its subsidiaries, designs, manufactures and sells high-grade customized and off-the-shelf power system solutions. Our products are used in the most demanding communications, industrial, medical and military applications where customers demand high density, high efficiency and rugged power solutions. The Company’s wholly owned subsidiary, Coolisys Technologies, Inc., is dedicated to providing world-class technology-based solutions where innovation is the main driver for mission-critical applications and lifesaving services. Coolisys’ growth strategy targets core markets that are characterized by “high barriers to entry” and include specialized products and services not likely to be commoditized. Coolisys Technologies, Inc., a developer and manufacturer that services the defense, aerospace, medical and industrial sectors, has three subsidiaries including Digital Power Limited dba Gresham Power Ltd., www.GreshamPower.com, a manufacturer based in Salisbury, UK; Microphase Corporation,www.MicroPhase.com with its headquarters in Shelton, CT 1-203-866-8000; and Power-Plus Technical Distributors, www.Power-Plus.com, a wholesale distributor based in Sonora, CA 1-800-963-0066.

Digital Power Lending, LLC, is a wholly owned subsidiary of the Company, is based in Fremont, CA, and is a California private lending company dedicated to strategically providing capital to small and middle size businesses for an equity interest in addition to loan fees and interest, www.DigitalPowerLending.com. Excelo, LLC, a wholly-owned subsidiary of the Company, is a national search firm specializing in fulfilling strategic executive, professional and hi-tech placements for businesses delivering world-class services, www.Excelo.com. Digital Power Corporation’s headquarters is located at 48430 Lakeview Blvd., Fremont, California, 94538; 1-877-634-098; www.DigiPwr.com.

For Investor inquiries: IR@digipwr.com, www.DigitalPowerCorp.com or 1-888-753-2235.

Forward-Looking Statements

The foregoing release contains “forward looking statements” regarding future events or results within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements concerning the Company’s current expectations regarding revenues for the remaining 2017 and thereafter from contracts and operations on a consolidated basis. The Company cautions readers that such “forward looking statements” are, in fact, predictions that are subject to risks and uncertainties and that actual events or results may differ materially from those anticipated events or results expressed or implied by such forward- looking statements. The Company disclaims any current intention to update its “forward looking statements,” and the estimates and assumptions within them, at any time or for any reason. More information about potential risk factors that could affect the Company’s business and financial results are included in the Company’s most recent filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company’s Forms 10-K, 10-Q and 8-K. All filings are available on the Company’s website at www.DigitalPowerCorp.com.

$CIIX OptHemp Line Achieves a Big Hit with Product Launch

• OptHemp Product Line successfully launched on Amazon and Alibaba
• CBD Magic Hemp Series generated 40,000 views and the purchase of over 91 units just minutes into launch
• CIIX offering is an innovative product line in what CBD Biotechnology believes to be an untapped segment of China’s booming skin care market

ChineseInvestors.com, Inc. (OTCQB: CIIX), in partnership with its foreign enterprise, CBD Biotechnology Co. Ltd. and through its subsidiary ChineseHempOil.com, Inc. has successfully launched its OptHemp product Line via a Top 100 platinum level seller on Amazon.com (NASDAQ: AMZN) and on China’s largest e-commerce retailer Alibaba. During its debut broadcast of “China Taobao Live Broadcasting Celebrity Show,” the company’s “CBD Magic Hemp Series” generated 40,000 views and the purchase of over 91 units just minutes into launch. ChineseInvestors.com CEO Warren Wang indicated in the news release that the product line’s successful initial launch on Taobao “solidifies our belief that Chinese consumers recognize that the anti-inflammatory agents and anti-oxidants contained in hemp-extract can have positive effects on the skin.”

According to Markets Insider (http://cnw.fm/Ks5H9), the CBD Magic Hemp Series is the company’s first line of hemp-infused skin care products (the CBDBIO TECH Brightening and Refreshing Moisturizer, CBDBIO TECH Perfecting Shield Primer and CBDBIO TECH Peptide Collagen Solution).  The products are intended to bring a moisturizing balance, form a protective layer, provide an even skin tone, and firm the skin while reducing the signs of aging. Different from other skin care lines currently available in China, the products are infused with non-industrial…

Read more »

More from CannabisNewsWire

• Medical Cannabis Payment Solutions (REFG) Integrates Cryptocurrency Payment Options
• Marijuana Company of America, Inc. (MCOA) Offers Promising Portfolio in Cannabis and Hemp
• Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is “One to Watch”

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$MPVD Announces Extension of Lenders’ Waiver

Shares Issued and Outstanding: 160,245,166
TSX and NASDAQ: MPVD

TORONTO and NEW YORK, Nov. 24, 2017 – Mountain Province Diamonds Inc. (“Mountain Province”, the “Company”) (TSX and NASDAQ: MPVD) today announces that it has received an extension of the waiver for the funding of the remaining reserve accounts under its project lending facility, until January 31, 2018 with unanimous consent of the lenders. Highlights of the waiver that has been agreed to between the Company and its lenders include (all amounts in US dollars):

• Sunk Cost and Debt Service Reserve Account funding is deferred until January 31, 2018
• Current Cash Cost Reserve Account funding of $25 million is deemed satisfactory until March 31, 2018
• Initial principal payment of $24.8 million, along with quarterly accrued interest, remains scheduled for December 31, 2017, in accordance with the original amortization schedule

Mountain Province Interim President and CEO David Whittle commented: “The receipt of this waiver is an important step as we continue to advance our near-term resolution to the project lending facility. The support of our lending group throughout this process has been very much appreciated.”

Mountain Province Diamonds is a 49% participant with De Beers Canada in the Gahcho Kué diamond mine located in Canada’s Northwest Territories. Gahcho Kué is the world’s largest new diamond mine, consisting of a cluster of four diamondiferous kimberlites, three of which are being developed and mined under the initial 12 year mine plan.

Caution Regarding Forward Looking Information
This news release contains certain “forward-looking statements” and “forward-looking information” under applicable Canadian and United States securities laws concerning the business, operations and financial performance and condition of Mountain Province Diamonds Inc. Forward-looking statements and forward-looking information include, but are not limited to, statements with respect to estimated production and mine life of the project of Mountain Province; the realization of mineral reserve estimates; the timing and amount of estimated future production; costs of production; the future price of diamonds; the estimation of mineral reserves and resources; the ability manage debt; capital expenditures; the ability to obtain permits for operations; liquidity; tax rates; and currency exchange rate fluctuations.  Except for statements of historical fact relating to Mountain Province, certain information contained herein constitutes forward-looking statements.  Forward-looking statements are frequently characterized by words such as “anticipates,” “may,” “can,” “plans,” “believes,” “estimates,” “expects,” “projects,” “targets,” “intends,” “likely,” “will,” “should,” “to be”, “potential” and other similar words, or statements that certain events or conditions “may”, “should” or “will” occur.  Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are based on a number of assumptions and subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements.  Many of these assumptions are based on factors and events that are not within the control of Mountain Province and there is no assurance they will prove to be correct.

Factors that could cause actual results to vary materially from results anticipated by such forward-looking statements include variations in ore grade or recovery rates, changes in market conditions, changes in project parameters, mine sequencing; production rates; cash flow; risks relating to the availability and timeliness of permitting and governmental approvals; supply of, and demand for, diamonds; fluctuating commodity prices and currency exchange rates, the possibility of project cost overruns or unanticipated costs and expenses, labour disputes and other risks of the mining industry, failure of plant, equipment or processes to operate as anticipated.

These factors are discussed in greater detail in Mountain Province’s most recent Annual Information Form and in the most recent MD&A filed on SEDAR, which also provide additional general assumptions in connection with these statements. Mountain Province cautions that the foregoing list of important factors is not exhaustive. Investors and others who base themselves on forward-looking statements should carefully consider the above factors as well as the uncertainties they represent and the risk they entail. Mountain Province believes that the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.

Although Mountain Province has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Mountain Province undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. Statements concerning mineral reserve and resource estimates may also be deemed to constitute forward-looking statements to the extent they involve estimates of the mineralization that will be encountered as the property is developed.

Further, Mountain Province may make changes to its business plans that could affect its results.  The principal assets of Mountain Province are administered pursuant to a joint venture under which Mountain Province is not the operator. Mountain Province is exposed to actions taken or omissions made by the operator within its prerogative and/or determinations made by the joint venture under its terms. Such actions or omissions may impact the future performance of Mountain Province. Under its current project finance facility Mountain Province is not permitted to pay dividends on common stock unless and until obligations under the facility have been satisfied. The declaration of dividends is at the discretion of Mountain Province’s Board of Directors, subject to restrictions under the Company’s project finance facility, and will depend on Mountain Province’s financial results, cash requirements, future prospects, and other factors deemed relevant by the Board.

$SHLD & St. Jude Children’s Hospital to Ring $NDAQ Bell

ADVISORY, Nov. 24, 2017 —

What:
St. Jude Children’s Research Hospital® is leading the way the world understands, treats and defeats childhood cancer and other life-threatening diseases. St. Jude will visit the Nasdaq MarketSite in Times Square along with Kmart, a mass merchandising company and subsidiary of Sears Holdings Corporation (Nasdaq:SHLD). Since 2006, Kmart has raised more than $105 million for St. Jude kids, more than any company in the history of St. Jude. This visit will highlight Kmart’s continued efforts to meet incredible goals this holiday season – continuing to raise awareness and funds for St. Jude Children’s Research Hospital during the annual St. Jude Thanks and Giving campaign.

In honor of the occasion, David George, VP/GM Retail Services and Rick Trksak, DGM for NYC from Kmart will ring the Opening Bell alongside Steele Ford, Senior Vice President, Strategic Partnerships at St. Jude and St. Jude patients.

Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:
Monday, November 27, 2017 – 9:15 a.m. to 9:30 a.m. ET

St. Jude Media Contact:
Hillary Karsten
(212) 843-9313
hkarsten@rubenstein.com

Kmart Media Contact:
Larry Costello
Sears Holdings
(847) 286-9036
Larry.Costello@searshc.com

Nasdaq MarketSite Media Contact:
Emily Pan
(646) 441-5120
emily.pan@nasdaq.com

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/

Webcast:
A live stream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.

About St. Jude Children’s Research Hospital:
St. Jude Children’s Research Hospital is leading the way the world understands, treats and defeats childhood cancer and other deadly diseases. St. Jude has the world’s best survival rates for the most aggressive childhood cancers, and treatments invented at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since we opened more than 50 years ago. St. Jude is working to drive the overall survival rate for childhood cancer to 90 percent, and we won’t stop until no child dies from cancer. St. Jude freely shares the discoveries we make, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food – because all a family should worry about is helping their child live. Join the St. Jude mission by visiting stjude.org or following St. Jude on facebook.com/stjude and twitter.com/stjude.

About Kmart:
Kmart, a wholly owned subsidiary of Sears Holdings Corporation (NASDAQ:SHLD), is a mass merchandising company and part of Shop Your Way, a social shopping experience where members have the ability to earn points and receive benefits across a wide variety of physical and digital formats through shopyourway.com. Kmart offers customers quality products through a portfolio of exclusive brands that include Jaclyn Smith, Joe Boxer, Route 66 and Smart Sense. For more information, visit the company’s website at kmart.com | Sears Holdings Corporation website at www.searsholdings.com | Facebook: facebook.com/kmart | Twitter: twitter.com/kmart | Instagram: Instagram.com/kmart

About Sears Holdings Corporation:
Sears Holdings Corporation (NASDAQ:SHLD) is a leading integrated retailer focused on seamlessly connecting the digital and physical shopping experiences to serve our members – wherever, whenever and however they want to shop. Sears Holdings is home to Shop Your Way®, a social shopping platform offering members rewards for shopping at Sears and Kmart as well as with other retail partners across categories important to them. The Company operates through its subsidiaries, including Sears, Roebuck and Co. and Kmart Corporation, with full-line and specialty retail stores across the United States. For more information, visit www.searsholdings.com

About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com

$YNDX and Uber in Russia Merger gets Federal Antimonopoly Service Approval

MOSCOW, Nov. 24, 2017 — The Federal Antimonopoly Service of the Russian Federation has approved the agreement between Yandex (NASDAQ:YNDX) and Uber to combine their ride-sharing businesses in Russia. The Ministry of Antimonopoly Regulation and Trade of the Republic of Belarus has also approved the transaction in Belarus. The decision of the antimonopoly service of Kazakhstan is still pending.

After the closing of the transaction, consumers will be able to use both Yandex.Taxi and Uber apps, while the driver-side apps will be integrated, leading to shorter passenger wait times, increased driver utilization rates, and higher service reliability.

Per the terms of the agreement, announced on July 13, 2017, the parties will contribute their ride-sharing businesses in Russia, Kazakhstan, Azerbaijan, Armenia, Belarus, and Georgia to a new holding company.

Uber will invest $225 million and Yandex will invest $100 million in cash in the new company at closing, valuing it at $3.725 billion on a post-money basis. After these investments, and subject to certain adjustments at closing, the new company will be owned approximately 59.3% by Yandex, 36.6% by Uber, and 4.1% by employees of the company, on a fully diluted basis. Uber will also contribute its UberEATS business in the region to the new company.

To ensure seamless service for riders and drivers, the parties intend to close the transaction after the Christmas and New Year’s holidays, in January 2018.

About Yandex
Yandex (NASDAQ:YNDX) is a technology company that builds intelligent products and services powered by machine learning. Our goal is to help consumers and businesses better navigate the online and offline world. Since 1997, we have delivered world-class, locally relevant search and information services. Additionally, we have developed leading on-demand transportation services, navigation products, and other mobile applications for millions of consumers across the globe. Yandex, which has 17 offices worldwide, has been listed on the NASDAQ since 2011.

About Uber
Uber’s mission is to provide reliable transportation everywhere, for everyone. We started in 2010 to solve a simple problem: how do you get a ride at the touch of a button? Six years and more than five billion trips later, we’ve started tackling an even greater challenge: reducing congestion and pollution in our cities by getting more people into fewer cars.

This press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the anticipated closing of the transaction described above, the successful combination of the two businesses, and the impact of such transaction on Yandex’s financial results. Actual results may differ materially from the results predicted or implied by such statements. The potential risks and uncertainties that could cause actual results to differ from the results predicted or implied by such statements include, among others, the satisfaction of the conditions to closing, the risks inherent in complex business combinations, and the impact of macroeconomic and geopolitical developments affecting the Russian and regional economy, as well as those risks and uncertainties included under the captions “Risk Factors” and “Operating and Financial Review and Prospects” in our Annual Report on Form 20-F for the year ended December 31, 2016, which is on file with the Securities and Exchange Commission and is available on our investor relations website at http://ir.Yandex.com/sec.cfm and on the SEC website at www.sec.gov. All information in this release is as of November 24, 2017, and Yandex undertakes no duty to update this information unless required by law.

For press enquiries, please contact:

Yandex:
Yandex press office:
Ochir Mandzhikov, Asya Melkumova
+7 495 739-70-00
pr@yandex-team.ru

Yandex.Taxi press office:
Vladimir Isaev
+7 495 739-70-00
pr@yandex-team.ru

Uber:
press@uber.com

$NKTR Phase III Amikacin Inhale Results in Gram-negative Pneumonia

WHIPPANY, N.J., Nov. 24, 2017 — Bayer today announced that INHALE, a global Phase III clinical study program investigating Amikacin Inhale in addition to standard of care in intubated and mechanically ventilated patients with Gram-negative pneumonia, did not demonstrate superiority versus standard of care plus aerosolized placebo. The primary endpoint, as well as secondary endpoints were similar in both treatment arms, and were therefore not met. Amikacin Inhale is the development name of an integrated drug-device combination, consisting of a specially formulated Amikacin Inhalation Solution and a proprietary Synchronized Inhalation System with a vibrating mesh nebulizer.

The primary outcome measure was survival at day 28-32. Secondary outcome measures included pneumonia-related mortality through to day 28-32, early clinical response up to day 10, number of days on mechanical ventilation up to day 28-32, and number of intensive care unit (ICU) days up to day 28-32. Efficacy and safety analyses from this study will be published in due course.

“New treatment options are needed for difficult-to-treat Gram-negative pneumonia in intubated and mechanically ventilated patients in the intensive care unit setting, as morbidity and mortality remain significant in these patients^1,2,” said Aleksandra Vlajnic, M.D., Vice President of Medical Affairs at Bayer.

About Amikacin Inhale
Amikacin Inhale (BAY 41-6551) is the development name for an investigational integrated drug-device combination product, in development by Bayer, comprised of a specially formulated Amikacin Inhalation Solution with Nektar Therapeutics’ (NKTR) proprietary Synchronized Inhalation System. Amikacin Inhale was studied in the INHALE phase 3 clinical trial program, in combination with standard of care IV antibiotics for the treatment of intubated and mechanically ventilated patients with Gram-negative pneumonia.

About the Phase III program INHALE
The global INHALE program is a multinational, randomized, placebo-controlled, double-blind, multi-center study program which investigated the clinical efficacy and safety of Amikacin Inhale in combination with standard of care IV antibiotics over standard of care IV antibiotics and aerosolized placebo for the treatment of Gram-negative pneumonia in adult patients who are intubated and mechanically ventilated.

The program included 725 patients. Eligible patients were randomized into 2 arms. Patients in the first arm received 400 mgs of Amikacin Inhale (BAY 41-6551) every 12 hours for 10 days administered using the Synchronized Inhalation System. Patients in the comparator arm received aerosolized placebo every 12 hours for 10 days, also administered using the using the Synchronized Inhalation System. Both groups received standard of care IV antibiotics following American Thoracic Society (ATS) guidelines or local guidelines.

The Amikacin Inhale program is being developed through a collaboration with Nektar Therapeutics (NASDAQ: NKTR).

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.us.

© 2017 Bayer
Bayer and the Bayer Cross are registered trademarks of Bayer.

Our online press service is just a click away: press.bayer.com

Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: https://twitter.com/BayerPharma

Media Contacts:
David Patti, +1-973-452-6793
Bayer, Product Communications
david.patti@bayer.com

Bayer Forward Looking Statement
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer Web site at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

For U.S. Media Only

¹ Ibrahim EH et al., “Experience with a clinical guideline for the treatment of ventilator-associated pneumonia,” Critical Care Medicine, vol. 29, pp. 1109-15, 2001.
² American Thoracic Society and the Infectious Diseases Society of America. Guidelines for the management of adults with HAP, VAP, HCAP. Am J Respir Crit Care Med 2005;171:388-416

$SPIL & $ASE Receive All Antitrust Approvals

TAIPEI, Taiwan, Nov. 24, 2017 — Advanced Semiconductor Engineering, Inc. (TWSE Code: 2311, NYSE Code: ASX) (“ASE“) and Siliconware Precision Industries Co., Ltd. (“SPIL“)(Taiwan Stock Exchange: 2325, NASDAQ: SPIL) jointly announced on June 30, 2016 that both companies plan to establish ASE Industrial Holding Co., Ltd. (“HoldCo“). Following the announcement, ASE and SPIL filed applications to antitrust authorities in different jurisdictions in connection with the proposed transaction. ASE and SPIL received clearances from the Taiwan Fair Trade Commission and the U.S. Federal Trade Commission on November 16, 2016 and May 15, 2017, respectively. On November 24, 2017, the Anti-Monopoly Bureau under the Ministry of Commerce of the PRC (“MOFCOM“) announced that it has conditionally approved the proposed transaction. ASE and SPIL highly appreciate the assistance that we have received from cross-strait and all relevant governmental authorities during the review process for this transaction. Since ASE and SPIL have now received all necessary antitrust clearances for the transaction, ASE will immediately proceed with the establishment of HoldCo. It is expected that an extraordinary general meeting will be convened in February 2018 and the establishment of HoldCo will be completed by the end of May 2018. This timeline, however, is subject to the review progress of competent authorities.

The combination of ASE and SPIL in the form of a joint share exchange (the “Share Exchange“) could promote healthy competition, enhance research and development intensity and provide high-quality and customized services to all customers. More importantly, the Share Exchange could contribute to the development of technical support for the advancement of the next-generation digital age. While the Share Exchange carries positive significance for Taiwan and benefits the development of the semiconductor packaging and testing technology in the PRC and across the globe, ASE and SPIL are aware of the fact that certain industry players and authorities in the PRC may have concerns over the potential restrictive effects of the Share Exchange. In order to mitigate such concerns, ASE and SPIL filed a remedial proposal to MOFCOM, which included the companies’ commitments to maintain independent operations for a confined period.

HoldCo will continue to list in Taiwan and in the US. ASE and SPIL will continue to expand our investment in Taiwan, to cherish and protect this land that nurtured us. In addition, we will continue to hold ourselves to the highest corporate governance standards and implement sustainable business philosophies. As an integral member of the global semiconductor industry chain, HoldCo would undoubtedly face severe competition and challenges. In order for HoldCo to compete effectively in the global environment, HoldCo will need to rely on the continued support and supervision from government authorities and all sectors of the society. More importantly, HoldCo will need to implement dynamic strategies to compete for talent and resources on a worldwide basis. In order to achieve our long-term goal for a sustainable industry and to enhance the welfare of the greater population, HoldCo will continue to work with other industry participants to explore strategic alliance opportunities, which will in turn spur further innovation and create a mutually beneficial business environment for the industry as a whole.

Safe Harbor Notice:

This statement contains “forward-looking statements” within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended, including statements regarding ASE’s or HoldCo’s future results of operations and business prospects. Although these forward-looking statements, which may include statements regarding the expected completion of the proposed combination between ASE and Siliconware Precision Industries Co., Ltd. (“SPIL”) and any benefits or synergies of the proposed combination, as well as ASE’s or HoldCo’s (if established) future results of operations, financial condition or business prospects, are based on certain assumptions made by ASE or HoldCo (if established) based on management’s experience, perception of historical trends and technical analyses, current conditions, anticipated future developments and other factors believed to be appropriate and reasonable by management as well as information from other sources ASE’s management believes to be reliable, you should not place undue reliance on these forward-looking statements, which apply only as of the date of this statement. The words “will,” “potential,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “may,” “could,” “project,” or their negatives, and other similar expressions or statements, as they relate to ASE or HoldCo (if established), are intended to identify these forward-looking statements, although not all forward-looking statements contain such identifying words. These statements discuss future expectations, identify strategies, contain projections of results of operations of ASE’s or HoldCo’s (if established) financial condition, or state other forward-looking information. Known and unknown risks, uncertainties and other factors could cause the actual results to differ materially from those contained in any forward-looking statement. These include risks and uncertainties that may affect the proposed combination with SPIL, the satisfactory completion of due diligence by the parties, the ability of the parties to negotiate and enter into a definitive agreement and, if such an agreement is entered into, the satisfaction of the conditions contained in the definitive agreement, any delay or inability to obtain necessary approvals or consents from third parties and the ability of the parties to realize the anticipated benefits from the proposed business transaction. ASE cannot guarantee that its expectations expressed in these forward-looking statements will turn out to be correct. ASE’s or HoldCo’s (if established) actual results could be materially different from and worse than those expectations. For a discussion of important risks and factors that could cause ASE’s or HoldCo’s (if established) actual results to be materially different from its expectations, please see the documents we file from time to time with the U.S. Securities and Exchange Commission (“U.S. SEC”), including ASE’s 2016 Annual Report on Form 20-F filed on April 21, 2017. Any forward-looking statement speaks only as of the date on which such statement is made and ASE undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

This statement is not an offering of securities for sale in any jurisdiction:

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of the U.S. Securities Act of 1933, as amended, or an exemption therefrom. ASE may file a registration statement on Form F-4 with the U.S. SEC in connection with the proposed joint share exchange between ASE and SPIL (the “Joint Share Exchange”). The Form F-4 will contain a prospectus and other documents. The Form F-4 and prospectus, as they may be amended from time to time, will contain important information about ASE, SPIL, the Joint Share Exchange and related matters. U.S. shareholders of ASE are urged to read the Form F-4, the prospectus and the other documents, as they may be amended from time to time, that may be filed with the U.S. SEC in connection with the Joint Share Exchange carefully before they make any decision at any shareholders’ meeting of ASE with respect to the Joint Share Exchange. The Form F-4 , the prospectus and all other documents filed with the U.S. SEC in connection with the Joint Share Exchange will be available when filed, free of charge, on the U.S. SEC’s website at www.sec.gov. In addition, the Form F-4 , the prospectus and all other documents filed with the U.S. SEC in connection with the Joint Share Exchange will be made available, free of charge, to U.S. shareholders of ASE who make a written request to ir@aseglobal.com.

Investor Relations Contact:

$TLGT Announces First FDA Generic Approval of Hydrocortisone Butyrate Lotion 0.1%

BUENA, N.J., Nov. 22, 2017 — Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Hydrocortisone Butyrate Lotion 0.1%.  This is Teligent’s ninth approval for 2017, and its nineteenth approval from its internally-developed pipeline of topical generic pharmaceutical medicines.

Based on recent QuintilesIMS Health data from September 2017, the total addressable market for this product is approximately $17.0 million.

“Hydrocortisone Butyrate Lotion 0.1% is Teligent’s ninth FDA approval in 2017,’’ commented Jason Grenfell-Gardner, President and CEO of the Company. “We submitted this ANDA on August 31, 2016, pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).  As we were the first ANDA applicant to submit an ANDA with a paragraph IV certification for Hydrocortisone Butyrate Lotion, 0.1%, with this approval Teligent is eligible for 180 days of generic drug exclusivity for Hydrocortisone Butyrate Lotion, 0.1%.  We expect to launch this product in the first quarter of 2018.”

Mr. Grenfell-Gardner continued, “I would like to commend our team for delivering another first-cycle approval from the FDA in less than 15 months from our filing date.  We now have twenty-four topical generic pharmaceutical products in the US portfolio, in addition to our four US injectable products.”

About Teligent, Inc.

Teligent is a specialty generic pharmaceutical company.  Our mission is to be a leading player in the specialty generic prescription drug market.  Learn more on our website www.teligent.com.

Forward-Looking Statements

This press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as “plan,” “believe,” “continue,” “should” or words of similar meaning. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to complete successfully future product acquisitions.  These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption “Risk Factors” in Teligent, Inc.’s most recent Annual Report on Form 10-K,  Quarterly Reports on Form 10-Q and other periodic reports we file with the Securities and Exchange Commission.  Teligent, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

Contact:
Jenniffer Collins
Teligent, Inc.
(856) 697-4379
www.teligent.com

$MEIP to Host Annual Meeting of Stockholders

Live Webcast from San Diego on November 30th

SAN DIEGO, Nov. 22, 2017 — MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host its Annual Meeting of Stockholders at 9:00 a.m. Pacific time on Thursday, November 30, 2017, at the Company’s headquarters, located at 3611 Valley Centre Drive, Suite 500, San Diego, CA 92130.  Stockholders of record at the close of business on October 4, 2017 are entitled to receive notice of and vote at the Annual Meeting. A live webcast of the meeting will be accessible at www.meipharma.com. A replay will be available approximately one hour after its conclusion.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s portfolio of drug candidates includes pracinostat, an oral HDAC inhibitor that is partnered with Helsinn Healthcare, SA. Pracinostat has been granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for use in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. Pracinostat is also being developed in combination with azacitidine in patients with high and very high-risk myelodysplastic syndrome (MDS). MEI Pharma’s clinical development pipeline also includes ME-401, a highly differentiated oral PI3K delta inhibitor currently in a Phase Ib study in patients with relapsed/refractory CLL or follicular lymphoma, and voruciclib, an oral, selective CDK inhibitor shown to suppress MCL1, a known mechanism of resistance to BCL2 inhibitors. The Company is also developing ME-344, a novel mitochondrial inhibitor currently in an investigator-sponsored study in combination with bevacizumab for the treatment of HER2-negative breast cancer. Pracinostat, ME-401, voruciclib and ME-344 are investigational agents and are not approved for use in the U.S. For more information, please visit www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

$UEPS Bitstamp Partners with Net1’s Masterpayment for Cryptocurrency Purchases

$NXTD Responds to Shareholder Questions

MELBOURNE, Florida, November 22, 2017 —

NXT-ID, Inc. (NASDAQ: NXTD) (“NXT-ID” or the “Company”), a security technology company issued the following response to recent shareholder inquiries concerning the recent downward volatility of its stock.

Gino Pereira, Chief Executive Officer of NXT-ID commented, “We believe the strong downward pressure on the stock in the recent days is not reflective of the underlying value of our company. The prospects of the Company are unchanged from the information in the recently filed 10Q and on the related earnings call.

“On year-to-year basis, we continue to out-perform in terms of revenue, gross profit, and operating income, particularly through LogicMark, which continues to perform at record levels. As was announced recently, the activation of Garmin Pay represents the successful commercialization of FitPay’s payment platform, which means that subsidiary is on track to contribute to revenue early in 2018.”

Added Pereira, “Equally as important as a result of the recent financing, we’ve begun taking steps to opportunistically reduce our debt. While that resulted in some dilution, it better positions the Company to refinance our existing debt facility, which we are actively pursuing.  We have a number of significant business development opportunities that we are pursuing in Q4 2017 and remain confident that the Company is poised for continued significant growth in 2018.”

About NXT-ID, Inc.

NXT-ID, Inc. (NASDAQ: NXTD) provides a comprehensive platform of technology products and services that enable the Internet of Things (IoT). With extensive experience in access control, biometric and behavior-metric identity verification, security and privacy, encryption and data protection, payments, miniaturization and sensor technologies, NXT-ID develops and markets groundbreaking solutions for payment and IoT applications. Its industry-leading technology products and solutions include MobileBio®, a suite of biometric solutions that secure consumers’ mobile platforms, the Wocket™, a next-generation smart wallet and the Flye, a digital credit card developed in collaboration with WorldVentures.

NXT-ID includes three mobile and IoT-related subsidiaries: LogicMark, LLC, a manufacturer and distributor of non-monitored and monitored personal emergency response systems (“PERS”) sold through dealers/distributors and the United States Department of Veterans Affairs; Fit Pay, Inc., a proprietary technology platform that delivers end-to-end solutions to device manufacturers for contactless payment capabilities, credential management, authentication and other secure services within the IoT ecosystem, and 3D-ID LLC, which is engaged in biometric identification and authentication. Learn more about NXT-ID at www.nxt-id.com.

Forward-Looking Statements for NXT-ID: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.

NXT-ID Inc. Contact:
Corporate info: info@nxt-id.com

Media:
Chris Orlando
chris.orlando@nxt-id.com

D. Van Zant
+1-800-665-0411
press@nxt-id.com

$CLNT Enters into Conditional Share Swap Agreement with Marvel Finance

HONG KONG, Nov. 22, 2017 Cleantech Solutions International, Inc. (“Cleantech Solutions” or “the Company”) (“CLNT”) (Nasdaq: CLNT) today announced that its wholly-owned subsidiary, Vantage Ultimate Limited (“Vantage”), has entered into a conditional share swap agreement with Marvel Finance Limited (“Marvel”), to acquire Marvel’s 51% interest in the issued share capital of Integrated Media Technology Limited (“IMT”) (Nasdaq: IMTE). The terms of the agreement provide that Marvel shall transfer 51% of the issued share capital of IMT (which is valued at US$13,482,410, based on 1,348,241 ordinary voting shares at a price of US$10.00 per IMT share). In exchange, the Company shall issue a certain number of its shares of common stock, representing 19.5% of the issued and outstanding shares of CLNT, and a 5-year interest-free promissory note with a principal amount of US$11,482,410 to Marvel. The agreement is subject to various conditions, including entry into a definitive agreement satisfactory to both parties and legal and financial due diligence.

“We are excited about our collaboration with Dr. Herbert Ying Chiu Lee, Founder and CEO of IMT, as we explore the development of advanced technologies,” said Parkson Yip, COO of Cleantech Solutions. “Dr. Lee has extensive experience in technology research and development management, particularly in knowledge management systems and 3D autostereoscopic displays. We believe Dr. Lee will make valuable contributions that will enable CLNT to enhance our technological capabilities and advance our products and services in a more effective and customer-driven manner.”

There can be no assurances that the parties may enter into any agreement to do a transaction, and even if an agreement is entered into, there can be no assurances that such transaction will be consummated.

About Cleantech Solutions International

Cleantech Solutions International (“CLNT”), through its affiliated companies, designs, manufactures and distributes a line of proprietary high and low temperature dyeing and finishing machinery to the textile industry. The Company’s latest business initiatives are focused on targeting the technology and global sharing economy markets, by developing online platforms and rental business partnerships that will drive the global development of sharing through economical rental business models.

Safe Harbor Statement

This release contains certain “forward-looking statements” relating to the business of the Company and its subsidiary and affiliated companies and certain potential transactions that they may enter into. These forward looking statements are often identified by the use of forward looking terminology such as “believes,” “expects” or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website, including factors described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K for the year ended December 31, 2016 and in our Form 10-Q for the quarter ended September 30, 2017. All forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements.

Company Contacts:
Cleantech Solutions International, Inc.
Parkson Yip, Chief Operating Officer
E-mail: parkson.yip@cleantechsolutionsinternational.com
+852-31060372
Web: www.cleantechsolutionsinternational.com

Elaine Ketchmere, CFA
Compass Investor Relations
310-528-3031
eketchmere@compass-ir.com

$IGC Adjournment of Annual Meeting Voting for Proposals Three and Four to Dec 15, 2017

Seeks to Obtain a Quorum of Voting Stockholders Owning Shares as of October 5, 2017

BETHESDA, Md., Nov. 22, 2017 – India Globalization Capital, Inc. (NYSE American:IGC), adjourned again the voting for Proposals Three and Four from its Notice of Annual Meeting of Shareholders, dated October 5, 2017.  Proposal Three seeks approval of the grant of 1,900,000 shares of common stock to be granted from time to time to the Company’s current and new employees, advisors, directors, and consultants by the board of directors, pursuant to certain metrics including performance, vesting and incentive as set by the board of directors and or the CEO; and Proposal Four seeks approval of the issuance of up to 2,000,000 shares of the Company’s common stock to Bricoleur Partners, L.P.

The voting on these two proposals was adjourned to December 15, 2017 at 12:00 am Eastern Standard Time to allow the Company’s stockholders additional time to vote. Stockholders who have already voted do not need to recast their votes. Proxies previously submitted in respect of the meeting will be voted at the adjourned meeting unless properly revoked. During the period of the adjournment, the Company will continue to solicit proxies from its stockholders only with respect to the Proposals Three and Four of the Annual Meeting. No changes have been made in the proposals to be voted on by stockholders at the annual meeting. The Company’s proxy statement and any other materials filed by the Company with the SEC remain unchanged and can be obtained free of charge at the SEC’s website at www.sec.gov.

The Company encourages all stockholders who have not yet voted to do so before December 14, 2017 at 11:59 p.m., Eastern Standard Time. The stockholders may vote by internet at www.proxyvote.com, or by telephone at 800-454-8683, or by returning a properly executed proxy card to InvestorCom.

“We have two businesses: continuing legacy operations and canna-pharmaceuticals. We have filed six cannabis-based patents addressing various ailments and expect to make our most advanced and promising formulation, Hyalolex for Alzheimer’s, available to patients in select U.S. states in the first two months of 2018. Roughly 5.3 million individuals in the U.S. and 44 million worldwide suffer from this debilitating disease. Our formulation, Hyalolex, has been shown to address the primary indicators of Alzheimer’s, plaques and tangles, as well as alleviate several end points of the disease like anxiety and sleep disorder.  Importantly, this is achieved without the patient getting high, or suffering long-term damage to neurons,” states Ram Mukunda, IGC CEO.

About IGC:
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA.
For more information please visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/

Forward-looking Statements:
Please see forward-looking statements and risk factors as discussed in detail in IGC’s Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Contact at IGC:
Claudia Grimaldi
301-983-0998

Contact at InvestorCom, Inc.
Michelle Frosch
877-972-0090

$RIOT Appoints Investment Executive Frank M. Bishop to Advisory Board

CASTLE ROCK, Colo., Nov. 21, 2017 — Riot Blockchain, Inc. (Nasdaq: RIOT) (the “Company”) today announced that it has appointed Frank M. Bishop to the Riot Blockchain Advisory Board.  Mr. Bishop served as a member of the senior management team that built INVESCO into one of the largest publicly traded global investment management companies.  During Mr. Bishop’s tenure at INVESCO, he served as the President and Chief Executive Officer of both INVESCO Capital Management and INVESCO, Inc., the North American operating subsidiary of AMVESCAP, PLC, which later became INVESCO, Ltd. (NYSE: IVZ).

“Frank brings a great depth of finance and investment experience from his tenure as President and CEO of INVESCO,” commented John O’Rourke, Chairman and Chief Executive Officer of Riot Blockchain. “We are thrilled to have Frank join our Advisory Board, and look forward to his insight as we aim to become a leader in blockchain technologies.”

Mr. Bishop is presently the General Partner of AL III Management Co., an investment partnership with a focus on early stage equity investments. Additionally, Mr. Bishop serves as Chairman of the Board of MDL AutoMation, a systems and software provider to the retail automotive industry.  In his prior role at INVESCO, Mr. Bishop served as a director to multiple INVESCO management and advisory companies, including INVESCO Realty Advisors, INVESCO Management & Research, and PRIMCO Capital Management.

The blockchain is a decentralized and encrypted ledger that offers a secure, efficient, verifiable and permanent way of storing records and other information without the need for intermediaries. These protocols are the backbone of numerous digital cryptocurrencies, including Bitcoin, Ethereum and Litecoin. Blockchain protocols have a wide range of use, including processing transactions, accounting, verification and proof of ownership across a far-reaching spectrum of applications.

About Riot Blockchain

Riot Blockchain, Inc., (formerly Bioptix, Inc.) leverages its expertise and network to build and support blockchain technologies. It is establishing an Advisory Board with technical experience intending to become a leading authority and supporter of blockchain, while providing investment exposure to the rapidly growing Bitcoin and blockchain ecosystems. For more information, visit http://www.RiotBlockchain.com/.

The company continues to maintain its Bioptix business segment, including its royalty license stemming from an Exclusive License Agreement with Ceva Santé Animale S.A., providing an exclusive worldwide royalty-bearing license, until December 31, 2028, to develop, seek regulatory approval for and offer to sell, market, distribute, import and export luteinizing hormone and/or follicle-stimulating hormone products for cattle, equine and swine for the assistance and facilitation of reproduction.

Safe Harbor

The information provided in this press release may include forward-looking statements relating to future events or the future financial performance of the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipates,” “plans,” “expects,” “intends,” “will,” “potential,” “hope” and similar expressions are intended to identify forward-looking statements.  These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company’s periodic filings with the Securities and Exchange Commission, including the factors described in the sections entitled “Risk Factors”, copies of which may be obtained from the SEC’s website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.

Media Contacts
Karen Chase or Travis Kruse
Russo Partners, LLC
(646) 942-5627
(212) 845-4272
karen.chase@russopartnersllc.com
travis.kruse@russopartnersllc.com

Investor Contact
IR@RiotBlockchain.com

$RESN to Present at 10th Annual LD Micro Main Event

$ACIU to Host Key Opinion Leader Meeting on Tau IN Alzheimer’s

Lausanne, Switzerland, November 21, 2017 – AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will host a Key Opinion Leader (KOL) luncheon meeting on the importance of Tau as a target in Alzheimer’s disease and other neurodegenerative diseases on December 1, 2017 from 12.00pm – 1.45pm ET at the St. Regis Hotel, 2 E. 55th Street in New York, NY.

The meeting will feature presentations by KOLs Khalid Iqbal, PhD (New York State Institute for Basic Research in Developmental Disabilities) and Michael Rafii, MD, PhD (UC San Diego). They  will discuss the mechanism and importance of Tau in the pathology and treatment of Alzheimer’s and other neurodegenerative diseases, the role of diagnostics in Alzheimer’s and a review of research on Tau and Amyloid in people with Down syndrome.

AC Immune’s management team will provide an overview of the Company’s robust and diverse pipeline of nine therapeutic and three diagnostic product candidates. The Company has a clear strategy to invest and build value in each of the three pillars of its business — Alzheimer’s disease, other significant neurodegenerative diseases and neuro-orphan indications, and diagnostics.

A Q&A session with the featured KOLs and the management will follow the presentations.

This event is intended for institutional investors, sell-side analysts, and pharmaceutical business development professionals only. Please RSVP in advance if you plan to attend, as space is limited.

A live webcast and replay of the event will be available on the Investor Page of AC Immune’s website.

KOL Biographies

Khalid Iqbal, PhD
Dr. Khalid Iqbal is Professor and Chairman, Department of Neurochemistry at the New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York. He received his PhD in Biochemistry in 1969 from the University of Edinburgh, Edinburgh, U.K. Dr. Iqbal was the first to bulk-isolate neurofibrillary tangles and decipher their protein composition from autopsied brains of cases with Alzheimer’s disease in 1974. These pioneering studies led him to the discoveries of Tau protein as the major protein subunit of the tangles and its abnormal hyperphosphorylation in Alzheimer’s disease in 1986. Dr. Iqbal has received numerous awards, including the Potamkin Prize for Alzheimer Disease Research from the American Academy of Neurology, the Zenith Award from the Alzheimer’s Association, U.S.A and Honorary Doctor of Science degree from the City University of New York College of Staten Island. In 2007, Alzheimer’s Association, USA, established a Khalid Iqbal Life Time Achievement Award for Alzheimer’s Disease Research, which is given out annually at the International Conference on Alzheimer’s Disease (AAIC) to a senior established Alzheimer disease researcher. Dr. Iqbal has authored over 400 scientific papers in prestigious American and international scientific journals and edited seven books on research advances in Alzheimer’s disease and related neurodegenerative disorders. He currently serves on editorial boards of several journals and scientific advisory committees of biotechnology companies.

Michael Rafii, MD, PhD
Dr. Michael Rafii, MD, PhD, is a board-certified neurologist and Associate Professor of Neuroscience and Founding Director of the Adult Down Syndrome Clinic at UC San Diego. Dr. Rafii leads multiple research programs studying the link between Alzheimer’s disease and Down syndrome. He completed a fellowship in dementia and cognitive disorders at UC San Diego. He completed his neurology residency at the Johns Hopkins Hospital, where he was chief resident. He received his medical and doctorate degrees from Brown University School of Medicine and conducted neurogenetics research at Harvard Medical School. Dr. Rafii serves on the National Task Group on Intellectual Disabilities and Dementia Practices of the American Academy of Developmental Medicine and is co-editor of the textbook Common Pathogenic Mechanisms between Down Syndrome and Alzheimer’s Disease: Steps toward Therapy. Dr. Rafii received the Star Award from the Down Syndrome Association of San Diego for his efforts to improve the lives of people with this condition. He is also Clinical Director of the Alzheimer’s Therapeutic Research Institute (ATRI) at the Keck School of Medicine of USC.

About AC Immune
AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as Alzheimer’s disease (AD). The Company’s pipeline features nine therapeutic and three diagnostic product candidates. The most advanced of these is crenezumab, an anti-Abeta antibody in Phase 3 clinical studies for AD that is being conducted by the collaboration partner Genentech. Other collaborations include Biogen, Janssen Pharmaceuticals, Nestlé Institute of Health Sciences, Piramal Imaging and Essex Bio-Technology.

Forward Looking Statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information-Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission.  Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

For further information, please contact:

$DMPI Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM

40% of recurrent GBM patients treated to date achieved stable disease as measured by magnetic resonance imaging (MRI)

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 21, 2017  — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, today provided an overview of three scientific posters presented at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) held on November 16-19, 2017 in San Francisco, CA.

DelMar reported that 96% of patients enrolled were alive at the time of the analysis and 40% of patients enrolled were reported to have achieved stable disease as assessed by MRI following treatment with VAL-083 as a single agent.  “While it is too early to interpret overall survival results from this study, the substantial disease control observed to date in the treatment recurrent GBM, ‎an aggressive tumor that can double in size within 6-8 weeks, is an important and positive observation at this stage,” said Mr. Saiid Zarrabian, DelMar’s Interim Chief Executive Officer.

“The promising early observations from our ongoing Phase 2 clinical trial of VAL-083 as a potential new treatment option for MGMT-unmethylated GBM are also supported by extensive preclinical research into VAL-083’s unique mechanism of action,” added Mr. Zarrabian.  “Based on these recent data, we believe VAL-083 represents a potential solution for some of the most important unmet medical needs in the treatment of GBM and other central nervous system tumors.”

DelMar provided an update on the company’s ongoing Phase 2 clinical studies in a poster entitled “Clinical Trials with dianhydrogalactitol (VAL-083) in MGMT-unmethylated Glioblastoma,” which is being conducted in collaboration with The University of Texas MD Anderson Cancer Center. This trial is designed to enroll up to 48 patients to determine if VAL-083 treatment improves overall survival compared to historical reference control.

• DelMar reported that 27 subjects have been screened and 15 have been enrolled since the opening of recruitment in February 2017. To date, the trial has enrolled at a rate ahead of initial projections.
• All patients enrolled in the study have recurrent MGMT-unmethylated GBM with radiographic evidence of progression and were not surgically resected at the time of enrollment.
• DelMar reported that 96% of patients enrolled were alive at the time of the analysis and 40% of patients enrolled were reported to have achieved stable disease following treatment with VAL-083 as a single agent, as assessed by MRI.
• Enrollment is ongoing and median survival has not yet been reached in the trial.
• In general, VAL-083 treatment was well tolerated by patients with observed side effects (myelosuppression) similar to prior clinical experience.

The Company also provided an overview of the design a separate Phase 2 clinical trial of VAL-083 for newly diagnosed MGMT-unmethylated GBM patients on this poster. In this trial, which was recently initiated at Sun Yat-Sen University Cancer Center, patients will be treated with VAL-083 plus radiotherapy as an alternative to standard-of-care temozolomide plus radiation in the front-line setting. The trial is designed to enroll up to 30 patients with MGMT-unmethylated GBM to determine if VAL-083 treatment improves progression free survival (PFS) compared to a historical reference control. This trial is being supported though DelMar’s collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd.

In addition, DelMar also presented two additional pre-clinical posters during the conference:

• The Distinct Cytotoxic Mechanism of Dianhydrogalactitol (VAL-083) Overcomes Chemoresistance and Provides New Opportunities for Combination Therapy in the Treatment of Glioblastoma.

VAL-083 induces potent anti-cancer activity against treatment-resistant cells from glioblastoma, lung, prostate and ovarian tumors through a distinct mechanism of action.  Cancer cells treated with VAL-083 exhibit persistent DNA double-strand breaks and activation of the homologous DNA repair (HR) system. Activation of the HR system is an indicator of VAL-083’s unique anti-tumor activity.

When combined with topoisomerase or PARP inhibitors, the treatment effect of VAL-083 is increased in a synergistic or super-additive manner. Taken together, these data support the broad potential of VAL-083 as a new treatment against a wide range of cancers both as a single agent and in combination with other established cancer therapies.

• Dianhydrogalactitol (VAL-083) Overcomes Chemoresistance in Pediatric Malignant Brain Tumors and Displays Synergy with Topoisomerase Inhibitors

Pediatric high-grade glioma (HGG) and medulloblastoma are aggressive childhood brain tumors with a high incidence of recurrence and very few patients achieve long-term survival.  VAL-083 demostrates potent activity as a single agent against both chemo-resistant pediatric HGG and medulloblastoma independent of p53 status. DelMar also reported that VAL-083 potentiates radiotherapy and exhibits synergy when used in combination with topoisomerase inhibitors, two regimens commonly used in the treatment of childhood brain tumors.

“We continue to be highly enthusiastic about the potential of VAL-083 as a novel treatment for cancer patients who have limited or no treatment options,” added Mr. Zarrabian. “The excellent work performed by our world class academic research collaborators and our in-house team presented at the SNO meeting showcases VAL-083’s potential both as a single agent and as a component of combination therapeutic regimens.”

DelMar’s poster presentations can be viewed in their entirety on DelMar’s website at http://www.delmarpharma.com/scientific-publications.html

About VAL-083

VAL-083 (dianhydrogalactitol) is a “first-in-class”, DNA-targeting agent that introduces interstrand DNA cross-links at the N7-position of guanine leading to DNA double-strand breaks and cancer cell death. VAL-083 has demonstrated clinical activity against a range of cancers including GBM and ovarian cancer in historical clinical trials sponsored by the U.S. National Cancer Institute (NCI).  DelMar has demonstrated that VAL-083’s anti-tumor activity is unaffected by common mechanisms of chemoresistance in vitro. Further details regarding these studies can be found at http://www.delmarpharma.com/scientific-publications.html.

VAL-083 has been granted an orphan drug designation by the U.S. FDA Office of Orphan Products for the treatment of glioma, medulloblastoma and ovarian cancer, and in Europe for the treatment of malignant gliomas.

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals is focused on the development and commercialization of new therapies for cancer patients who have limited or no treatment options.  By focusing on understanding tumor biology and mechanisms of treatment resistance, the Company identifies biomarkers to personalize new therapies in indications where patients are failing, or have become resistant to modern targeted or biologic treatments.

The Company’s current pipeline is based around VAL-083, a “first-in-class,” small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers including central nervous system, ovarian and other solid tumors (e.g. NSCLC, bladder cancer, head & neck) in clinical trials sponsored by the NCI. Based on DelMar’s internal research programs and these prior NCI-sponsored clinical studies, the Company is conducting clinical trials to support the development and commercialization of VAL-083 across multiple oncology indications to solve significant unmet medical needs.

VAL-083 is also being studied in two collaborator-supported, biomarker driven, Phase 2 clinical trials for MGMT-unmethylated GBM. Overcoming MGMT-mediated resistance represents a significant unmet medical need in the treatment of GBM.  DelMar also recently announced the allowance of a separate IND for VAL-083 as a potential treatment for platinum-resistant ovarian cancer.

Further information on DelMar’s clinical trials can be found on clinicaltrials.gov:  https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs

For further information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989.

Connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

$VRML Release of Final CMS Reimbursement Rate for OVA1

AUSTIN, Texas, Nov. 20, 2017 — ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and the exclusive distributor of OVA1 (Multivariate Index Assay) (MIA), and Overa (MIA2G), today announced that the Center for Medicare Services (CMS) has released the Final 2018 Clinical Lab Fee Schedule, effective January 1, 2018.

Under the new fee schedule, the price for OVA1(MIA) (code 81503) is $897.  This is a four-fold increase over the current CMS rate, and this new rate is based on the median of private payer payments submitted to CMS by companies, including ASPiRA Labs, as part of the market-based payment reform mandated through Protecting Access to Medicare Act of 2014 (PAMA). The rate is scheduled to be in effect for a three-year term from January 2018 thru December 2020.

“We are very excited that CMS has finally priced OVA1 based on market pricing which is directly related to improved patient outcomes and health economic impact.  Historically, pricing has not reflected OVA1’s benefit to improved patient outcomes, as well as the cost reductions to the healthcare system,” stated Valerie Palmieri, President and Chief Executive Officer of Vermillion, Inc. “Our health economics study published last week is another confirmation of the value of our technology.  In addition to being appropriately priced, OVA1 is now included on the Clinical Lab Fee Schedule (CLFS) for the very first time.  We expect that leveraging guidelines, payer coverage and price will be key catalysts for growth in 2018.”

“The inclusion of OVA1 on the CLFS should accelerate our contracting efforts throughout 2018,” stated Fred Ferrara, Chief Operating Officer of ASPiRA Labs.  “Several large plans use the CLFS to determine price.  We view the added CLFS visibility for our testing that was calculated using the PAMA rates as a very positive event.  We plan to expand the ASPiRA Labs sales team in strategic markets to deliver OVA1 to more women going forward, particularly given the substantial increase in covered lives expected to take effect from October 2017 through February 2018.”

The lifetime risk for all U.S. women to develop a pelvic mass is 20%. There is a 5-10% lifetime risk of requiring surgery for a suspected ovarian neoplasm. Due to the majority of the masses are benign, triaging the low and high risk masses is vital to improved patient outcomes. Today, more than 60% of U.S. ovarian cancer patients do not receive National Comprehensive Cancer Network (NCCN) guideline treatment, which includes surgical treatment by a gynecologic oncologist, and, as a result, the survival rate is reduced by 30-40%. OVA1 helps ensure that rare ovarian cancer is triaged appropriately to the gynecological oncologist and benign cysts are managed by the general practitioner, in a very cost-effective and efficient way. Vermillion’s goal is to have the right patient managed by the right specialist, with the right treatment the first time.

OVA1 is now considered a Level B Recommendation by The American College of Obstetricians and Gynecologists (ACOG). Given the November 2016 ACOG bulletin, the 2017 NCCN update and the 2013 Society of Gynecologic Oncology positive position statement, OVA1 can be the physician’s first choice in biomarker panels to best triage patients’ pelvic masses to the most appropriate care pathway. There is no other comparable technology on the market today.

CMS also published a final price for Overa of $752, which was benchmarked to the only proteomic test currently on the CLFS that uses biomarkers and an algorithm to produce a prognostic score. The price for Overa will be re-reviewed now that OVA1 is on the CLFS.

Links to multiple clinical studies showing OVA1’s strong performance compared to existing technologies, such as CA125 and ROMA, can be found on our website:

http://vermillion.com/providers/ova-1/clinical-validation-studies/.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases.  The company’s initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2^nd Generation (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.

Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding the expected catalysts for Vermillion’s growth, the anticipated impact of the inclusion of OVA1 on the CLFS on Vermillion’s contracting efforts, plans to expand the ASPiRA Labs sales team and expected increases in the number of covered lives. Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on Vermillion’s expectations as of the date of this press release. A variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements, including changes to interpretations of existing laws and regulations and other factors that are described in Vermillion’s Form 10-K for the year ended December 31, 2016 and Form 10-Q for the quarter ended March 31, 2017 as filed with the Securities and Exchange Commission. Vermillion expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law.

Investor Relations Contact:
Michael Wood
LifeSci Advisors LLC
Tel 1-646-597-6983
mwood@lifesciadvisors.com

$CLSN Publication of the Study of ThermoDox

Collaboration with University of Oxford to Execute a Clinical Trial Using Focused Ultrasound and ThermoDox® for Primary and Metastatic Liver Cancer

Presentation of TARDOX Study Phase I Findings at the Upcoming RSNA 2017 Annual Meeting

First Ever Study Evaluating ThermoDox® with Focused Ultrasound in Humans

LAWRENCEVILLE, N.J., Nov. 20, 2017 — Celsion Corporation (NASDAQ:CLSN) today announced publication of the manuscript, “Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours,” in the Journal of Therapeutic Ultrasound 2017 5:28.

The article describes the clinical trial design for the TARDOX Study. This proof of concept study was designed to demonstrate the safety and feasibility of targeted drug release and enhanced delivery of doxorubicin from thermally sensitive liposomes (ThermoDox®) triggered by mild hyperthermia induced by focused ultrasound in primary and metastatic solid liver tumors.

• The primary outcome measures for the study was the direct quantification of the doxorubicin concentration before and after focused ultrasound (FUS) mediated hyperthermia from tumor biopsies, using high performance liquid chromatography (HPLC).
• The secondary outcome measures for the study relate to the safety and feasibility of inducing controlled FUS-mediated targeted hyperthermia in the target tumor non-invasively in order to achieve ThermoDox® release.

The TARDOX Study, which is supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, was carried out as a multi-disciplinary collaboration between Celsion, the Oxford University Institute of Biomedical Engineering (Prof. Constantin Coussios), the Oncology Clinical Trials Office (OCTO) and the Oxford University Hospitals NHS Foundation Trust (Prof. Fergus Gleeson, Radiology and Prof. Mark Middleton, Oncology). The first author is Dr. Paul Lyon (academic clinical fellow, Oxford University Hospitals NHS Foundation Trust) and the article is available online in the November 2, 2017 issue of the Journal of Therapeutic Ultrasound:

https://jtultrasound.biomedcentral.com/articles/10.1186/s40349-017-0104-0

“Both Celsion and Oxford believe there is significant potential when combining ThermoDox® with focused ultrasound to treat a broad range of malignancies, including primary liver cancer,” said Michael H. Tardugno, Celsion’s chairman, president and chief executive officer. “TARDOX, the ThermoDox®/Focused Ultrasound trial, is an important step in demonstrating that ultrasound-induced hyperthermia can enable the highly targeted delivery of chemotherapeutic agents to tumors non-invasively. This represents another unquestionable example confirming ThermoDox®’s mechanism of action in a clinical setting and further establishes that ThermoDox® may be used with multiple heating technologies allowing for successful targeting of a broad range of primary and metastatic solid tumors with high concentrations of chemotherapy.”

The Company also announced that an abstract for the TARDOX Study has been accepted for presentation at the Radiological Society of North America (RSNA) 2017 Annual Meeting which will take place from November 26, 2017 – December 1, 2017 at the McCormick Center in Chicago, IL.

• The abstract, entitled “Clinical Results of a Phase I First in Man Study of Targeted Delivery of Lyso-thermosensitive Liposomal Doxorubicin by Extracorporeal Focused-Ultrasound Hyperthermia for Liver Tumours,” will be presented by Dr. Paul Lyon on Monday, November 27, 2017 at 11:40 am (local time) during Vascular Interventional (10-Liver Cancer) Session – Room E352.
• The presentation will summarize clinical findings from all patients treated in the TARDOX Study, a Phase I clinical study of ThermoDox®, Celsion’s heat-activated liposomal encapsulation of doxorubicin, in combination with focused ultrasound to treat primary and metastatic liver cancer.

Professor Constantin-C. Coussios, senior author and Director of the Institute of Biomedical Engineering at the University of Oxford, commented, “This clinical program builds upon many years of experience with ultrasound-guided HIFU, as well as laboratory studies of ThermoDox® release by ultrasound, at our institution since 2007. This is the first study in humans to explore extra corporeally triggered drug release and targeted drug delivery in oncology. We look forward to exploring the combination of ThermoDox®, a well-characterized anti-cancer therapy triggered by heat, with focused ultrasound to cause hyperthermia, rather than ablation, non-invasively. We are excited by the potential of this combination to advance treatment within a significantly underserved population.”

About ThermoDox®

Celsion’s most advanced program is a heat-mediated, tumor-targeting drug delivery technology that employs a novel heat-sensitive liposome engineered to address a range of difficult-to-treat cancers. The first application of this platform is ThermoDox®, a lyso-thermosensitive liposomal doxorubicin (LTLD), whose novel mechanism of action delivers high concentrations of doxorubicin to a region targeted with the application of localized heat at 40°C, just above body temperature. In one of its most advanced applications, ThermoDox®, when combined with radiofrequency thermal ablation (RFA), has the potential to address a range of cancers. For example, RFA in combination with ThermoDox® has been shown to expand the “treatment zone” with a margin of highly concentrated chemotherapy when treating individual primary liver cancer lesions. The goal of this application is to significantly improve efficacy.

Celsion’s LTLD technology leverages two mechanisms of tumor biology to deliver higher concentrations of drug directly to the tumor site. The first: Rapidly growing tumors have leaky vasculature, which is permeable to liposomes and enables their accumulation within tumors. Leaky vasculature influences a number of factors within the tumor, including the access of therapeutic agents to tumor cells. Administered intravenously, LTLD is engineered to allow significant accumulation of liposomes at the tumor site at the time of radiofrequency ablation as these liposomes recirculate in the blood stream. The second: When the tumor tissue is heated to a temperature of 40°C or greater, the heat-sensitive liposome rapidly changes structure and the liposomal membrane selectively dissolves, creating openings that release the chemotherapeutic agent directly into the tumor and into the surrounding vasculature. Drug concentration increases as a function of the accumulation of liposomes at the tumor site, but only where the heat is present. This method targets only the tumor and the area related to tumor invasion, supporting precise drug targeting.

About Celsion Corporation

Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company’s lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com (CLSN-LTSL/ThermoDox®)

About the NIHR Oxford Biomedical Research Centre

The NIHR Oxford Biomedical Research Centre (BRC) is based at the Oxford University Hospitals NHS Foundation Trust and run in partnership with the University of Oxford, funded by the National Institute for Health Research (NIHR).

The NIHR improves the health and wealth of the nation through research. Established by the Department of Health, the NIHR:

• funds high quality research to improve health
• trains and supports health researchers
• provides world-class research facilities
• works with the life sciences industry and charities to benefit all
• involves patients and the public at every step

For further information, visit the NIHR website www.nihr.ac.uk.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data, particularly in small subgroups that are not statistically significant; FDA and regulatory uncertainties and risks; the significant expense, time, and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion’s periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Celsion Investor Contact

Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com

$OHGI Regains Full Compliance with NASDAQ Listing Requirements

LONDON, Nov. 20, 2017 —  One Horizon Group, Inc. (NASDAQ:OHGI) (“Company”) today announced that it received a letter from the NASDAQ Listing Qualifications Staff (“Staff”) on November 15, 2017, notifying the Company that it has regained compliance with The NASDAQ Capital Market’s minimum stockholders’ equity requirement under NASDAQ Listing Rules 5550(b)(1), 5550(b)(2) or 5550(b)(3) (“Rules”) for continued listing on The NASDAQ Capital Market and that Staff considers the matter closed.

On August 22, 2017, Staff notified the Company that it did not comply with the minimum $2.5 million stockholders’ equity, or $35 million market value of listed securities, or $500,000 of net income from continuing operations requirements for The NASDAQ Capital Market as required by the Rules.

However, based on the Form 10-Q for the period ended September 30, 2017, filed on November 14, 2017, reporting stockholders’ equity of $4,427,000, Staff has determined that the Company complies with the Rules and this matter is now closed.

On November 7, 2017, the Company announced that it received a letter from the Staff on November 6, 2017, notifying the Company that it had regained compliance with The NASDAQ Capital Market’s minimum bid price requirement under Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market and that Staff considers that matter closed as well.

Therefore, in accordance with the Staff letters of November 15, 2017, and November 6, 2017, the Company is in full compliance with the applicable NASDAQ Listing Requirements.

About One Horizon Group, Inc.

One Horizon Group, Inc. (NASDAQ:OHGI) is a reseller of secure messaging software for the growing gaming, security and education markets including in China and Hong Kong.  For more information on the Company please visit http://www.onehorizongroup.com/investors-overview/.

Darrow Associates Contacts for OHGI

Bernie Kilkelly
(516) 236-7007
bkilkelly@darrowir.com

Jordan Darrow
(512) 551-9296
jdarrow@darrowir.com

$ACST Development and Commercialization with Leading China Pharma Partner

Acasti Contact:
Jan D’Alvise, Chief Executive Officer
450-686-4555
info@acastipharma.com
www.acastipharma.com

Media Contact:
Jessica Dyas, Canale Communications
619-849-5385
jessica@canalecomm.com

Investor Relations Contact:
Glen Akselrod, Bristol Capital Ltd.
(905) 326-1888 ext 10
glen@bristolir.com

$IGC Reports Second Quarter 2018 Financial Results and Operational Highlights

BETHESDA, Md., Nov. 20, 2017 — India Globalization Capital, Inc. (NYSE American:IGC), today reported financial results for the second quarter ended September 30, 2017 and provided an overview of recent operational highlights.

“Our initial focus on the canna-pharmaceutical front is on Alzheimer’s, America’s most expensive disease.  In 2017, the direct cost of treatment for Alzheimer’s and other dementias is projected to cost the U.S. approximately $259 billion.  In the U.S., roughly 5.3 million individuals suffer from the disease and the number is expected to double over the next 20 years.  Worldwide, approximately 43 million individuals suffer from the disease, and there is no cure.  Independent of our longer-term FDA clinical trial process, our near-term goal is to commercialize our liquid formulation for Alzheimer’s as a Complimentary and Alternative Medicine (CAM) sold through licensed medical cannabis dispensaries in the U.S., and internationally in Canada and Germany,” stated Ram Mukunda, CEO of IGC.

In May 2017, we acquired exclusive rights to a patent filed by the University of South Florida Research Foundation entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease”.  It is believed that in Alzheimer’s disease two types of legions in the brain are implicated in the pathogenesis of the disease: (1) senile plaque composed of amyloid beta peptides (Aβ plaque), and (2) neurofibrillary tangles, composed of highly phosphorylated Tau protein.  Amyloid Precursor Protein (APP), on the surface of neurons, is normally cleaved by enzymes to free up Aβ peptide composed of 36-43 amino acids that is then cleared by the body. In patients with Alzheimer’s, an imbalance causes Aβ to be unregulated, resulting in the abnormal buildup into insoluble fibrils depositing as senile plaques. Aβ monomers aggregate to form oligomers and then into fibril Aβ. It is believed that extracellular misfolded oligomers are toxic to nerve cells. IGC’s Alzheimer’s drug candidate, IGC-AD1, has been shown to work through a molecular pathway that allows IGC-AD1 to: 1) modulate Aβ protein production, 2) inhibit Aβ protein aggregation, 3) reduce Tau phosphorylation, 4) enhance mitochondria function, and 5) possibly help redirect the immune system, with none of the side effects commonly associated with cannabis. Based on these and other studies, we expect to bring IGC-AD1 to market in early 2018, with the hope of bringing much needed relief to Alzheimer’s patients.

In addition, we made progress on our six provisional patent filings in the phytocannabinoid-based combination therapy space for the indications of pain, medical refractory epilepsy, and cachexia. The table below provides a status of the patent filings:

Results of Operations

Revenue – We have two lines of business: (a) “legacy”, consisting of rental of heavy equipment, commodities trading, and real estate management, and (b) “canna-pharmaceutical”. Total revenue from the legacy business was $235,648 for the three months ended September 30, 2017 as compared to $162,163 for the three months ended September 30, 2016.  The increase was primarily driven by increased volume of business.

Cost of Revenue (excluding depreciation) – Cost of revenue for the three months ended September 30, 2017 was $163,170 as compared to $90,534 for the three months ended September 30, 2016.  The increase in cost of revenue stems from an increase in the volume of the legacy business.

Selling, General and Administrative – Selling, general and administrative expenses were $331,146 for the three months ended September 30, 2017 as compared to $339,585 for the three months ended September 30, 2016.

Depreciation – The depreciation expense was approximately $4,344 in the three months ended September 30, 2017 as compared to $97,842 in the three months ended September 30, 2016.  The decrease in depreciation is from the curtailment of the iron-ore mining business in China.

Interest and other financial expenses – The interest expense and other financial expenses for the three months ended September 30, 2017 were approximately $40,832 as compared to approximately $51,410 for the three months ended September 30, 2016.  Most of the interest is paid with common shares of the Company and is therefore non-cash.

Other income/(loss) – Other income was $(144) for the three-month period ended September 30, 2017 as compared to $11,985 in September 30, 2016. Other income includes income from the supply of skilled operators for the legacy heavy equipment rental business.

Consolidated Net Income/(loss) – In the three months ended September 30, 2017, the Company reported a GAAP net income loss of $303,804 and a GAAP EPS loss of $0.01 compared to a GAAP net income loss of $583,871 and a GAAP EPS loss of $0.02 for the three months ended September 30, 2016.

At the end of September 30, 2017, our cash and cash equivalents along with restricted cash was $597,026 and working capital of $803,769. We expect to raise money for the canna-pharmaceutical business, specifically to immediately begin marketing IGC-AD1.

About IGC:
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA.

For more information please visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/

Forward-looking Statements:
Please see forward-looking statements and risk factors as discussed in detail in IGC’s Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Contact:
Claudia Grimaldi
301-983-0998

FINANCIAL TABLES TO FOLLOW

See accompanying Notes to Consolidated Financial Statements below in this report and Notes to the Audited Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2017 filed with the SEC on July 14, 2017.

See accompanying Notes to Consolidated Financial Statements below in this report and Notes to the Audited Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2017 filed with the SEC on July 14, 2017.

$CIIX CBD Biotech Enterprise Partners with Chinese Beauty Influencer

$LE Offers Chance To Be Santa For a Day

Chance to Win $10,000, a $5,000 Donation to Charity of Choice, Sacks of Presents and Lands’ End Gift Cards

DODGEVILLE, Wis., Nov. 17, 2017 — The holiday season is here and Lands’ End will once again embrace the spirit of giving through the Santa for a Day campaign. The generous giving initiative will award sacks of presents and an abundance of gift cards as well as offer incredible product promotions and the chance to personally win $10,000 through the Santa for a Day sweepstakes.

“Santa has always represented the true spirit of giving and through the Santa for a Day campaign we are able to extend that magic and give others the chance to be as generous as our old friend from the North Pole this holiday season,” said Matt Trainor, SVP of Brand Creative at Lands’ End. “Whether it’s through incredible personalized gifts and unique promotions, an engaging social initiative or events in local markets where the search is on for ‘Santas,’ we are on a mission to celebrate the spirit of giving this season and continue to be ‘Holiday Makers’.”

Santa Goes Social: #santaforaday
Aspiring gift givers can participate daily in the #santaforaday social campaign from November 28 – December 17 on Twitter. Each day a unique Santa interview question will be asked at @LandsEnd; participants can answer using #santaforaday and #LandsEndHoliday to be entered for a chance to win a $100 Lands’ End gift card. Winners will be selected at random. The gift card prizes are an effort to help aspiring Santas fulfill gift lists this holiday season.

Santa for a Day in Minneapolis and Chicago Area
Lands’ End will spread holiday cheer in Minneapolis and the Chicago area by offering the chance to be Santa for a Day. Event attendees in each city will be invited to call the Santa Hotline in an iconic red phone booth and speak with Santa for a chance to be selected as a Santa for a Day.  Selected “Santas” from each city will each receive a sack of presents and have the chance to share in the spirit of giving.

Win and Give Santa for a Day Sweepstakes
Lands’ End is also offering one lucky winner the chance to truly be Santa for a Day through a holiday sweepstakes. Now through December 17, 2017, everyone can enter for a chance to win $10,000 in cash, as well as $5,000 for a charity of choice (to be approved by Lands’ End).  To enter daily, fill out the form at landsend.com/santaforaday.

Santa For A Day Instant Win
From now until Dec. 17, 2017, shoppers can also play the Lands’ End Santa for a Day Instant Win Game Sweepstakes for a chance to win a $1,000 Lands’ End gift card each week. For more information or to enter visit landsend.com/santaforaday.

About Lands’ End, Inc.
Lands’ End, Inc. (Nasdaq: LE) is a leading multi-channel retailer of clothing, accessories, footwear and home products. We offer products through catalogs, online at www.landsend.com and affiliated specialty and international websites, and through retail locations, primarily at Lands’ End Shops at Sears® and standalone Lands’ End Stores. We are a trusted American lifestyle brand with a passion for quality, legendary service and real value, and seek to deliver timeless style for men, women, kids and the home.

$AMRS DSM Expands Strategic Alliance, Acquires Brazilian Production Facility

HEERLEN, The Netherlands and EMERYVILLE, Calif., Nov. 17, 2017 — Royal DSM (AEX:DSM.AS), a global science-based company active in health, nutrition and materials and Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that they have enhanced their strategic alliance through the sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing partnership for Amyris’ high-volume products.

Total consideration for Amyris Brasil Ltda (which owns and operates the Brotas 1 production facility), intellectual property related to farnesene (a bio-based key intermediate for many applications) and an additional value share arrangement over a three-year period amounts to US$ 96 million. In addition to the consideration upfront there is potential for a future value share in line with Amyris’ business model.

DSM will continue existing supply-agreements to Amyris and other parties. DSM will also supply Amyris with specialty compounds until it realizes its Brotas 2 specialties production facility. Amyris is accelerating the construction of its second facility dedicated to specialty products while maintaining the manufacturing process development and business support capability located in Campinas, Brazil.

Subject to customary conditions, the transaction is expected to close in the next few months.

With the acquisition of the Brotas 1 facility, DSM adds a state-of-the-art biotechnology-based production site in Brazil to its global network, with abundant availability of sustainable raw materials (sugar cane), securing production capacity for its rich pipeline of sustainable and bio-based solutions. Having broad experience in operating large-scale fermentation plants, DSM will optimize the operational performance of the site.

The strategic alliance between DSM and Amyris started in May 2017 with an equity investment by DSM in Amyris, and has since been expanded with several significant product development collaborations.

The sale of the Brotas 1 facility, which was designed to produce high volumes of farnesene, together with the creation of a long-term production relationship for high-volume farnesene-based intermediates will enable Amyris to focus on its core strength of developing breakthrough bioscience technologies through a portfolio approach that continues to target key markets, as well as the production of specialty products.

“Following our equity investment in Amyris and subsequent product development cooperations, I am pleased that we can add a state-of-the-art fermentation-based production facility to our network. Our know-how in fermentation, downstream process development and large-scale manufacturing will allow us to further improve the operational performance of the facility while further strengthening our strategic alliance with Amyris,” said Chris Goppelsroeder, President & CEO of DSM Nutritional Products.

“We are very pleased with the continued expansion of our strategic alliance with DSM,” said John Melo, Amyris President & CEO. “This manufacturing partnership and the sale of our Brotas 1 factory allows us to accelerate the development and manufacturing of specialty, high-performance ingredients. We are building a specialty plant at Brotas (Brotas 2) and also expect to complete our São Martinho plant to focus on sweeteners. The combination of these actions provides us the manufacturing footprint to meet our current demand through the next 3-5 years and to manage this within our funding constraints.”

Continued Melo, “This transaction completes a planned shift from operating a plant originally designed to produce high volumes of farnesene, to producing an expanding number of high-value, specialty ingredients. This shift will allow Amyris to improve returns and cash flows in order to continue to provide sustainable growth for Amyris and its partners.”

DSM – Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com.

About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.

DSM Forward-Looking Statements
This press release may contain forward-looking statements with respect to DSM’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

Amyris Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as expected upfront consideration to Amyris in the transaction as well as future value share payments, the anticipated closing of the transaction, including the timing thereof, the expected continuation of existing supply agreements with Amyris and other parties, the anticipated supply of Amyris’s specialty compounds, the expected construction of the proposed Brotas 2 facility, the anticipated development and manufacturing of specialty ingredients, the expected construction of a proposed plant focused on sweeteners, anticipated ability to meet current and future demand, and expected improvements in returns, cash flows and growth), that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris’s liquidity and ability to fund operating and capital expenses, timing and execution risks associated with manufacturing, uncertainty regarding consummating proposed transactions, including the timing thereof, and growth in sales, potential delays or failures in development, production and commercialization of products, risks related to Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on August 14, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris, the Amyris logo and No Compromise are registered trademarks of Amyris, Inc. All other trademarks are trademarks of their respective owners.

For more information:

DSM Corporate Communications
Herman Betten
tel. +31 (0) 45 578 2017
e-mail media.contacts@dsm.com

Amyris, Inc.
Peter DeNardo
tel.: +1 (510) 740-7481
e-mail: investor@amyris.com
pr@amyris.com

DSM Investor Relations
Dave Huizing
tel.: +31 (0) 45 578 2864
e-mail: dave.huizing@dsm.com

$STKS Announces Closing of Strategic Financing

NEW YORK

The ONE Group Hospitality, Inc. (NASDAQ: STKS) today announced the closing of a strategic financing with Elevated Returns, LLC and Argyle Street Management Limited and another accredited investor to further strengthen the Company’s balance sheet and fund strategic initiatives. The Company appointed Mr. Kin Chan to the board of directors effective upon the closing of the financing.

Pursuant to a securities purchase agreement entered into on November 15, 2017, the investors purchased from the Company 1,750,000 shares of common stock at a price of $1.50 per share in a registered direct offering, resulting in total gross proceeds of $2.625 million. In a concurrent private placement, the Company also issued unregistered warrants to the investors to purchase up to an aggregate of 875,000 shares of common stock with an exercise price of $1.63 per share, which was the Nasdaq consolidated closing bid price per share on November 14, 2017. The warrants will be exercisable six months following the closing date and will expire five years from the date they become exercisable.

The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-203429), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on May 22, 2015. The warrants and shares issuable upon exercise of the warrants were offered in a concurrent private placement and have not been registered under the Securities Act of 1933, as amended. The Company has agreed to file a registration statement on Form S-1 with the SEC covering the resale of the shares of common stock issuable upon exercise of the warrants.

Manny Hilario, Chief Executive Officer of The ONE Group Hospitality, noted, “We are excited to announce this investment by Elevated Returns and Argyle Street Management Limited, as both firms have a strong history of investments in the hospitality industry. They also bring significant international experience, particularly throughout Asia, which is one of the largest potential growth opportunities we see for the STK brand. With Mr. Kin Chan being based in Hong Kong, we will now have representation at the Board level in the Far East to enable us to start to focus on expanding into that very lucrative market. This investment by Elevated Returns and Argyle Street Management Limited also strengthens our balance sheet and positions us well as we continue to grow our brand through global licensing opportunities.”

Mr. Kin Chan, founding shareholder and Chief Investment Officer of Argyle Street Management Limited, stated, “This investment demonstrates our confidence in The ONE Group Hospitality and the business strategy the management team is executing. We believe The ONE Group Hospitality has a global growth opportunity and we look forward to working with the Company.”

Effective upon the closing of the financing, Mr. Kin Chan was appointed to the Company’s Board of Directors replacing Nicholas Giannuzzi. Mr. Chan is also the Chairman of TIH Limited and a director of OUE Limited, both listed on the Singapore Exchange; an Independent Non-Executive Director of Mount Gibson Iron Limited, an Australia-listed mining company; and nonexecutive director of CITIC Resources Holdings Limited, a company listed in Hong Kong. Mr. Chan was an Executive Director at Goldman, Sachs & Co. where he worked in Hong Kong, New York and Singapore from 1992 to 1999. Mr. Chan holds an AB from Princeton University and MBA from Wharton School of the University of Pennsylvania where he was a Palmer Scholar.

Jonathan Segal, the Company’s Chairman, noted, “We are pleased to appoint Mr. Kin Chan to our board. Mr. Chan adds significant international hospitality experience and he has many strong relationships within the hospitality segment. As we focus on global growth through licensing opportunities, we believe that his vast experience could be a strong asset to our board.”

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About The ONE Group

The ONE Group Hospitality, Inc. (“The ONE Group”) (Nasdaq:STKS) is a global hospitality company that develops and operates upscale, high-energy restaurants and lounges and provides hospitality management services for hotels, casinos and other high-end venues both nationally and internationally. The ONE Group’s primary restaurant brand is STK, a modern twist on the American steakhouse concept with locations in major metropolitan cities throughout the U.S. and Europe. The ONE Group’s food and beverage hospitality services business, ONE Hospitality, provides the development, management and operations for premier restaurants and turn-key food and beverage services within high-end hotels and casinos. Additional information about The ONE Group can be found at www.togrp.com.

Cautionary Statement on Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements, including but not limited to, (1) our ability to open new restaurants and food and beverage locations in current and additional markets, grow and manage growth profitably, maintain relationships with suppliers and obtain adequate supply of products and retain our key employees; (2) factors beyond our control that affect the number and timing of new restaurant openings, including weather conditions and factors under the control of landlords, contractors and regulatory and/or licensing authorities; (3) in the case of our strategic review of operations, our ability to successfully improve performance and cost, realize the benefits of our marketing efforts, and achieve improved results as we focus on developing new management and license deals; (4) our ability to enter into licensing agreements; (5) changes in our management team; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (8) other risks and uncertainties indicated from time to time in our filings with the SEC, including our Annual Report on Form 10-K filed on April 5, 2017.

Investors are referred to the most recent reports filed with the SEC by The ONE Group Hospitality, Inc. Investors are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.

Investors:
ICR
Michelle Michalski, 646-277-1224

$TOUR Management Change and Preliminary Results for the Third Quarter of 2017

NANJING, China, Nov. 17, 2017  — Tuniu Corporation (NASDAQ: TOUR) (“Tuniu” or the “Company”), a leading online leisure travel company in China, today announced that Mr. Haifeng Yan, co-founder, President and Chief Operating Officer, and Mr. Conor Chia-hung Yang, Chief Financial Officer, will resign from their positions with the Company, effective November 17, 2017, for personal reasons. Mr. Yan will continue to serve as a member of the board of directors of the Company and Mr. Yang will serve as a senior consultant to the Company.

Tuniu has promoted Ms. Maria Yi Xin from Vice President of the Company to assume the position of Chief Financial Officer. Ms. Xin joined Tuniu in 2013 and has over 10 years of experience in corporate finance and capital markets with US-listed companies. While at Tuniu, Ms. Xin has held various key roles at the Company such as Vice President of investor relations, strategic investments and international media. Prior to Tuniu, Ms. Xin worked in equity research at China Renaissance, a leading financial institution in China. Prior to China Renaissance, Ms. Xin worked at E-Commerce China Dangdang Inc., a leading business-to-consumer e-commerce company in China then listed on the NYSE, and at New Oriental Education and Technology Group Inc. (NYSE: EDU), the largest provider of private educational services in China. Ms. Xin received Bachelor’s degrees in economics and law from Nankai University.

Mr. Dunde Yu, co-Founder, Chairman and Chief Executive Officer of the Company, said, “We would like to thank Mr. Yan and Mr. Yang for their contributions to Tuniu over the years. Although they will be stepping away from day-to-day operations, they will continue to work closely with Tuniu on the company’s strategy and business development. We are also very delighted to promote Ms. Xin to the role of Chief Financial Officer. Since joining Tuniu, Ms. Xin has been a key member of our team and has helped Tuniu in many areas. Together, we look forward to bringing Tuniu to new heights.”

Third Quarter 2017 Preliminary Results

For the third quarter of 2017, Tuniu currently estimates that its total net revenues will be in the range of RMB800.0 million to RMB810.0 million, above the previous guidance of RMB761.5 million to RMB787.7 million. Tuniu estimates that its non-GAAP net income will be in the range of RMB35.0 million to RMB40.0 million, as compared with a non-GAAP loss during the third quarter of 2016.

Ms. Maria Yi Xin, Chief Financial Officer, said, “We expect solid performance for the third quarter as our core leisure travel business continues to benefit from China’s growing demand for leisure travel. On the business operations side, Tuniu is leveraging its established brand, dynamic technology infrastructure and extensive supply chain to achieve greater efficiency. We will continue to scale our operation as the leader in China’s online leisure travel market and to unlock value for our shareholders.”

Tuniu to Report Third Quarter 2017 Financial Results on November 27, 2017 U.S. Time

Additional information regarding Tuniu’s results for the third quarter of 2017 will be available when Tuniu reports its quarterly results on November 27, 2017, at which time management will discuss the Company’s financial and business performance in more detail.

Tuniu’s management will hold an earnings conference call at 8:00 am U.S. Eastern Time on November 27, 2017 (9:00 pm Beijing/Hong Kong Time on November 27, 2017).

Listeners may access the call by dialing the following numbers:

A telephone replay will be available one hour after the end of the conference call through December 4, 2017. The dial-in details for the replay are as follows:

Additionally, a live and archived webcast of this conference call will be available at http://ir.tuniu.com/.

About Tuniu

Tuniu (Nasdaq:TOUR) is a leading online leisure travel company in China that offers a large selection of packaged tours, including organized and self-guided tours, as well as travel-related services for leisure travelers through its website tuniu.com and mobile platform. Tuniu has over 1,800,000 stock keeping units (SKUs) of packaged tours, covering over 400 departing cities throughout China and all popular destinations worldwide. Tuniu provides one-stop leisure travel solutions and a compelling customer experience through its online platform and offline service network. For more information, please visit http://ir.tuniu.com.

Safe Harbor Statement

This press release contains forward-looking statements made under the “safe harbor” provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Tuniu may also make written or oral forward-looking statements in its reports filed with or furnished to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about Tuniu’s beliefs and expectations, are forward-looking statements that involve factors, risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors and risks include, but are not limited to the following: Tuniu’s goals and strategies; the growth of the online leisure travel market in China; the demand for Tuniu’s products and services; its relationships with customers and travel suppliers; the Company’s ability to offer competitive travel products and services; Tuniu’s future business development, results of operations and financial condition; competition in the online travel industry in China; relevant government policies and regulations relating to the Company’s structure, business and industry; and the general economic and business condition in China and elsewhere. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is current as of the date of the press release, and Tuniu does not undertake any obligation to update such information, except as required under applicable law.

For investor and media inquiries, please contact:

China

Mary Chen
Investor Relations Director
Tuniu Corporation
Phone: +86-25-8685-3178
E-mail: ir@tuniu.com

$MICT Receives $1,900,000 New Order for its TREQ®-317 On Board Computer

Order from a leading ELD compliant U.S. telematics provider – Serves growing $10 billion mobile resources management market

MONTVALE, N.J., Nov. 17, 2017 — Micronet Enertec Technologies, Inc. (NASDAQCM: MICT), (the “Company”), announced today that its Mobile Resource Management (MRM) subsidiary, Micronet Inc., has received a purchase order from a current customer, a leading U.S. telematics service provider, valued at $1,900,000 for its TREQ®-317.

In the last 7 months Micronet has received orders for an aggregate of over $14 million, which it believes continues to demonstrate the strong demand for Micronet’s state of the art technological solutions for the telematics and the electronic logging device (ELD) market.

The TREQ®-317 is a rugged Android™ based fix-mount on board computer offering advanced functionality at a competitive price. Micronet’s TREQ®-317 enables its users to provide real-time monitoring of both vehicle and driver activity and is fully compliant with ELD regulations.

“We are very pleased to continue working with our valued customers. We believe that new orders from current customers are a clear indication of the value our products deliver in the MRM space. We believe that the continued and increasing demand for our advanced Android based computing systems supports Micronet in expanding its product offerings and becoming a leading provider in the rapidly expanding MRM/telematics market,” said David Lucatz, Chief Executive Officer of Micronet Enertec Technologies, Inc.

About Micronet Enertec Technologies, Inc.

Micronet Enertec Technologies, Inc. (NASDAQCM: MICT) provides high tech solutions for severe environments and the battlefield, including missile defense technologies for Aerospace & Defense and rugged mobile devices for the growing commercial MRM market. MICT designs, develops, manufactures and supplies customized military computer-based systems, simulators, automatic test equipment and electronic instruments, addressing the defense industry. Solutions and systems are integrated into critical systems such as command and control, missile fire control, maintenance of military aircraft and missiles for the Israeli Air Force, Israeli Navy and by foreign defense entities.  MICT’s MRM division develops, manufactures and provides mobile computing platforms for the mobile logistics management market in the U.S., Europe and Israel. American-manufactured systems are designed for outdoor and challenging work environments in trucking, distribution, logistics, public safety and construction.

Forward-looking Statements

This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. These forward-looking statements include, but are not limited to, those statements regarding the Company’s belief that new orders from current customers are a clear indication of the value its products deliver in the MRM space and demonstrate the strong demand for Micronet’s state of the art technological solutions for the telematics and the ELD market, as well as the Company’s belief that the continued and increasing demand for its advanced Android based computing systems supports Micronet in expanding its product offerings and becoming a leading provider in the rapidly expanding MRM/telematics market. Such forward-looking statements and their implications involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. The forward-looking statements contained in this press release are subject to other risks and uncertainties, including those discussed in the “Risk Factors” section and elsewhere in the Company’s annual report on Form 10-K for the year ended December 31, 2016 and in subsequent filings with the Securities and Exchange Commission. Except as otherwise required by law, the Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

$AFAM & $LHCG In-Home Healthcare Services Merger of Equals

• National platform enables greater service and continuity across continuum of care
• Well-positioned to lead the transition to value-based reimbursement through the highest quality and patient satisfaction
• Immediately accretive for the shareholders of each company
• $25 million in run-rate cost synergies identified
• Diversification of services and expansion of geographic footprint creates in-home healthcare provider and joint venture partner of choice for leading hospitals and health systems
• Well-capitalized balance sheet for continued growth through acquisitions
• Multi-channel growth opportunities accelerate organic growth, expand joint venture relationships and extend service lines

LAFAYETTE, La. and LOUISVILLE, Ky., Nov. 16, 2017 — LHC Group, Inc. (NASDAQ:LHCG) and Almost Family, Inc. (NASDAQ:AFAM) announced today that they have agreed to combine in an all-stock merger of equals transaction pursuant to a definitive merger agreement unanimously approved by the Boards of Directors of each company.

The merger will create a nationwide provider of in-home healthcare services with a long track record of successfully partnering with hospitals and health systems led by the most experienced management team steeped in home health. The combined company will have 781 locations in 36 states with more than 31,000 employees and revenue of $1.8 billion and Adjusted EBITDA of approximately $145 million for the trailing 12-month period ended September 30, 2017.

Compelling Strategic Rationale

• Industry Leadership: Creates the leading in-home healthcare company in the United States, with a large, national footprint and diversified lines of service as well as Centers for Medicare & Medicaid Services (CMS) Star ratings that outpace the industry. The combined company is well-positioned to lead the industry’s transition to value-based reimbursement and highly coordinated care.
• Accelerated Growth: The creation of a comprehensive in-home healthcare solution with home health, hospice and personal care services sets the stage for new channels of organic growth throughout the existing footprint. The combined company will be positioned as the preferred in-home healthcare partner to current and potential hospital joint venture partners as well as referral sources. A significant pipeline of joint ventures, extensions of existing relationships and acquisitions is expected to accelerate revenue growth.
• Immediate Accretion: The merger is expected to be immediately accretive to adjusted earnings per diluted share for both companies, and to generate identified pre-tax run-rate cost synergies of $25 million.
• Balance Sheet Flexibility: Combined gross leverage is expected to be 1.5x based on combined trailing 12-month 2017 Adjusted EBITDA as of September 30, 2017, pro forma for $25 million in cost synergies, which provides additional capacity to pursue new acquisition opportunities.
• Strong Cultural Fit and Shared Vision: A history of senior leadership collaboration within the in-home healthcare industry and a shared vision to shape the evolution of the U.S. healthcare delivery system to value-based reimbursement set the stage for an integration of naturally synergistic organizations. The ability to leverage technology to extend scale and share best practices among two industry leaders in quality and patient satisfaction creates a localized provider with an unrivaled commitment to delivering patient-centered care in the home.
• Industry Leading Management Team: The combined company is led by a management team with strong operational expertise, a proven track record of developing joint ventures with leading hospitals and health systems and a history of successful, efficient capital deployment.

Transaction Details
Under terms of the transaction, Almost Family shareholders will receive 0.9150 shares of LHC Group for each existing Almost Family share. Upon closing of the transaction, LHC Group shareholders will own 58.5% and Almost Family shareholders will own 41.5% of the combined company. The stock issuance in the merger is expected to be tax-free to shareholders of both companies. The transaction, which is expected to be completed in the first half of 2018, is subject to the receipt of regulatory approvals and other customary closing conditions as well as the approval of shareholders of both LHC Group and Almost Family.

The combined company will continue to trade on NASDAQ under the ticker symbol, “LHCG.” William Yarmuth, current chairman and chief executive officer of Almost Family, will remain as a special advisor to the combined company, while Steve Guenthner, current president and principal financial officer of Almost Family, will be named chief strategy officer. Keith Myers, current chairman and chief executive officer of LHC Group, will be named chairman and chief executive officer of the combined company, while Donald Stelly will be named president and chief operating officer and Joshua Proffitt will be named chief financial officer. The Board of Directors will be comprised of ten members, six of which (including Mr. Myers and Lead Independent Director Billy Tauzin) will be current LHC Group directors and four of which will be Almost Family directors. The combined companies’ Home Office will remain in Lafayette, La., and Personal Care Services, Healthcare Innovations and other support services will continue to operate out of Louisville, Ky.

Commenting on the announcement, Keith G. Myers, LHC Group’s chairman and CEO, said, “William Yarmuth and I have worked closely together on many of the important issues our industry has faced over the years, including the most recent home health advocacy with CMS, Office of Management and Budget and Congress. Almost Family shares our vision for making a difference in the communities we serve by delivering quality, outcomes-focused, patient-centered care to the most vulnerable in society. This merger is truly a transformative event for both our companies and our patients nationwide and a unique opportunity to bring more than 30,000 dedicated and talented employees together to lead the in-home healthcare industry’s transition to value-based reimbursement and highly coordinated care.”

William B. Yarmuth, Almost Family’s chairman and CEO, added, “In my opinion, we are combining two of America’s most successful home healthcare companies to create what will be the best-run, best-positioned in-home healthcare company in America.  The complementary nature of our two firms provides incredible fit, adding clinical, operational and financial strength, and depth without any meaningful conflicts or overlaps in management, geography, and service capabilities.  I believe the combined company will have the management team with the broadest and deepest experience of all the national in-home healthcare providers.

“By combining the best of both our long track records of success and patient-focused cultures, we will be able to accomplish much more together than either of us could possibly achieve alone.  I am extremely proud of the work we’ve done, the progress we’ve made, and the tremendous prospects for our future together. I look forward to working with Keith and the rest of the management team in the continued evolution of these companies.”

Jefferies LLC is serving as financial advisor to LHC Group and Alston & Bird LLP is serving as its legal advisor. Guggenheim Securities, LLC is serving as financial advisor to Almost Family and Gibson, Dunn & Crutcher LLP is serving as its legal advisor.

Conference Call
LHC Group and Almost Family will host a joint conference call today at 11:00 a.m. Eastern time to discuss the proposed merger. The toll-free number to call for this interactive teleconference is (866) 393‑1608 (international callers should call (973) 890-8327). A telephonic replay of the conference call will be available through midnight on November 23, 2017, by dialing (855) 859‑2056 (international callers should call (404) 537-3406) and entering confirmation number 1169538.

A live broadcast of the joint conference call as well as presentation materials will be available under the Investor tabs at www.LHCgroup.com and www.AlmostFamily.com.  A one-year online replay will be available approximately an hour following the conclusion of the live broadcast.

About LHC Group, Inc.
LHC Group, Inc. is a national provider of non-acute healthcare services, providing quality, cost-effective healthcare to patients primarily within the comfort and privacy of their home or place of residence. LHC Group provides a comprehensive array of healthcare services through home health, hospice, community‑based services agencies and facility-based services. LHC Group operates 320 home health services locations, 92 hospice locations, 12 community-based service locations and 15 long-term acute care hospitals (LTACHs).

About Almost Family, Inc.
Almost Family, Inc., founded in 1976, is a leading national provider of home healthcare services, with 332 branch locations in 26 states, including its joint venture with Community Health Systems, Inc.. Almost Family, Inc. and its subsidiaries operate home health, other home-based services and healthcare innovations segments.

Forward-Looking Statements
This press release contains “forward-looking statements” (as defined in the Securities Litigation Reform Act of 1995) regarding, among other things, future events or the future financial performance of LHC Group, Inc. (“LHC Group”) and Almost Family, Inc. (“Almost Family”). Words such as “anticipate,” “expect,” “project,” “intend,” “believe,” “will,” “estimates,” “may,” “could,” “should” and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. The closing of the proposed transaction is subject to the approval of the stockholders of LHC Group and Almost Family, regulatory approvals and other customary closing conditions. There is no assurance that such conditions will be met or that the proposed transaction will be consummated within the expected time frame, or at all. Forward-looking statements relating to the proposed transaction include, but are not limited to: statements about the benefits of the proposed transaction, including anticipated earnings accretion, synergies and cost savings and future financial and operating results; LHC Group’s and Almost Family’s plans, objectives, expectations, projections and intentions; the expected timing of completion of the proposed transaction; and other statements relating to the transaction that are not historical facts. Forward-looking statements are based on information currently available to LHC Group and Almost Family and involve estimates, expectations and projections. Investors are cautioned that all such forward-looking statements are subject to risks and uncertainties, and important factors could cause actual events or results to differ materially from those indicated by such forward-looking statements. With respect to the proposed transaction, these risks, uncertainties and factors include, but are not limited to: the risk that LHC Group or Almost Family may be unable to obtain governmental and regulatory approvals required for the transaction, or that required governmental and regulatory approvals may delay the transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; the risk that required stockholder approvals may not be obtained; the risks that the other condition(s) to closing of the transaction may not be satisfied; the length of time necessary to consummate the proposed transaction, which may be longer than anticipated for various reasons; the risk that the businesses will not be integrated successfully; the risk that the cost savings, synergies and growth from the proposed transaction may not be fully realized or may take longer to realize than expected; the diversion of management time on transaction-related issues; the risk that costs associated with the integration of the businesses are higher than anticipated; and litigation risks related to the transaction. With respect to the businesses of LHC Group and/or Almost Family, including if the proposed transaction is consummated, these risks, uncertainties and factors include, but are not limited to: changes in, or failure to comply with, existing government regulations that impact LHC Group’s and/or Almost Family’s businesses; legislative proposals for healthcare reform; the impact of changes in future interpretations of fraud, anti-kickback, or other laws; changes in Medicare and Medicaid reimbursement levels; changes in laws and regulations with respect to Accountable Care Organizations; changes in the marketplace and regulatory environment for Health Risk Assessments; decrease in demand for LHC Group’s or Almost Family’s services; the potential impact of the announcement or consummation of the proposed transaction on relationships with customers, joint venture and other partners, competitors, management and other employees, including the loss of significant contracts or reduction in revenues associated with major payor sources; ability of customers to pay for services; risks related to any current or future litigation proceedings; potential audits and investigations by government and regulatory agencies, including the impact of any negative publicity or litigation; the ability to attract new customers and retain existing customers in the manner anticipated; the ability to hire and retain key personnel; the risk that the credit ratings of the combined company or its subsidiaries may be different from what the companies expect and/or risks related to the ability to obtain financing; increased competition from other entities offering similar services as offered by LHC Group and Almost Family; reliance on and integration of information technology systems; ability to protect intellectual property rights; impact of security breaches, cyber-attacks or fraudulent activity on LHC Group’s or Almost Family’s reputation; the risks associated with assumptions the parties make in connection with the parties’ critical accounting estimates and legal proceedings; the risks associated with the combined company’s expansion strategy, the successful integration of recent acquisitions, and if necessary, the ability to relocate or restructure current facilities; and the potential impact of an economic downturn or effects of tax assessments or tax positions taken, risks related to goodwill and other intangible asset impairment, tax adjustments, anticipated tax rates, benefit or retirement plan costs, or other regulatory compliance costs.

Additional information concerning other risk factors is also contained in LHC Group’s and Almost Family’s most recently filed Annual Reports on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other Securities and Exchange Commission (“SEC”) filings.

Many of these risks, uncertainties and assumptions are beyond LHC Group’s or Almost Family’s ability to control or predict. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the information currently available to the parties on the date they are made, and neither LHC Group nor Almost Family undertakes any obligation to update publicly or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this press release. Neither LHC Group nor Almost Family gives any assurance (1) that either LHC Group or Almost Family will achieve its expectations, or (2) concerning any result or the timing thereof. All subsequent written and oral forward-looking statements concerning LHC group, Almost Family, the proposed transaction, the combined company or other matters and attributable to LHC Group or Almost Family or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above.

Additional Information And Where To Find It
The proposed transaction between LHC Group and Almost Family will be submitted to the respective stockholders of LHC Group and Almost Family for their consideration. LHC Group will file with the SEC a registration statement on Form S-4 that will include a joint proxy statement of LHC Group and Almost Family that also constitutes a prospectus of LHC Group. LHC Group and Almost Family will deliver the joint proxy statement/prospectus to their respective stockholders as required by applicable law. LHC Group and Almost Family also plan to file other documents with the SEC regarding the proposed transaction. This press release is not a substitute for any prospectus, proxy statement or any other document which LHC Group or Almost Family may file with the SEC in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF LHC GROUP AND ALMOST FAMILY ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT LHC GROUP, ALMOST FAMILY, THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and stockholders will be able to obtain free copies of the joint proxy statement/prospectus and other documents containing important information about LHC Group and Almost Family, once such documents are filed with the SEC, through the website maintained by the SEC at www.sec.gov. LHC Group and Almost Family make available free of charge at www.lhcgroup.com and www.almostfamily.com, respectively (in the “Investor” or “Investor Relations” section, as applicable), copies of materials they file with, or furnish to, the SEC.

Participants In The Merger Solicitation
LHC Group, Almost Family, and certain of their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of LHC Group and Almost Family in connection with the proposed transaction. Information about the directors and executive officers of LHC Group is set forth in its proxy statement for its 2017 annual meeting of stockholders, which was filed with the SEC on April 28, 2017. Information about the directors and executive officers of Almost Family is set forth in its proxy statement for its 2017 annual meeting of shareholders, which was filed with the SEC on April 7, 2017. These documents can be obtained free of charge from the sources indicated above. Other information regarding those persons who are, under the rules of the SEC, participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC when they become available.

No Offer or Solicitation
This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the proposed transaction between LHC Group and Almost Family or otherwise, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Non-GAAP Financial Information
This press release includes certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), including Adjusted EBITDA and Adjusted Earnings per Share. The companies use these non-GAAP financial measures in operating its business because management believes they are less susceptible to variances in actual operating performance that can result from the excluded items. The companies present these financial measures to investors because they believe they are useful to investors in evaluating the primary factors that drive the companies’ operating performance. The items excluded from these non-GAAP measures are important in understanding LHC Group’s and Almost Family’s financial performance, and any non-GAAP measures presented should not be considered in isolation of, or as an alternative to, GAAP financial measures. Since these non-GAAP financial measures are not measures determined in accordance with GAAP, have no standardized meaning prescribed by GAAP and are susceptible to varying calculations, these measures, as presented, may not be comparable to other similarly titled measures of other companies. Adjusted EBITDA of LHC Group and Almost Family is defined as net income (loss) before income tax benefit (expense), interest expense, depreciation and amortization expense, and transaction costs related to previous transactions. Adjusted Earnings per Share is defined as diluted earnings per share adjusted transaction costs related to acquisition activities, net of estimated tax benefit.

Contact:
Investors:
LHC Group
Eric Elliott
Senior Vice President of Finance
(337) 233-1307
eric.elliott@lhcgroup.com

Almost Family
Steven Guenthner
President and Principal Financial Officer
(502) 891-1000
steveguenthner@almostfamily.com

Media:
Schmidt Public Affairs
Rebecca Reid
(410) 212-3843
rreid@schmidtpa.com